[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"HANGZHOU ACOSOUND TECHNOLOGY CO., LTD.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":197},{"warningLetters":4,"total":196},[5,32,53,76,95,119,139,156,177],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},160,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-15T04:00:00Z\">04\u002F15\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-yiqi-biotechnology-co-ltd-720707-04152026\">Hangzhou Yiqi Biotechnology Co., Ltd  \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-66\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jack Chai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hangzhou Yiqi Biotechnology Co., Ltd  \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Room 204, Building 3, No. 66 Xixiang Road, Puyan Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hangzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>310018\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-66\u003C\u002Fp>\u003Cp>April 15, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Chai:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our June 16, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Hangzhou Yiqi Biotechnology Co., Ltd, FEI 3035145155, at Room 204, Building 3, No. 66 Xixiang Road, Puyan Street, Hangzhou, Zhejiang 310018, China.\u003C\u002Fp>\u003Cp>This Warning Letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for APIs.\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant deviations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm failed to conduct process validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> APIs manufactured at your facility. These APIs are for use in further processing to produce sterile drug products and for pharmaceutical compounding operations.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its life cycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>Without adequate process validation, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA’s guidance for industry \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed APIs.\u003C\u002Fli>\u003Cli>Also provide a risk assessment and any follow up actions to be taken for the distributed APIs produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to validate and verify the suitability of analytical methods.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm failed to perform test method validation or verification for each test method used for drugs distributed to the United States.\u003C\u002Fp>\u003Cp>Test methods must be validated to show that they are suitable for their intended use or verified to show at least equivalence with United States Pharmacopeia (USP) compendial methods. Method validation and verification are necessary to support reliable determinations of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that the data provided to customers were an accurate reflection of pharmaceutical product quality and safety.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each lot of your APIs before making a lot of disposition decisions, and the associated written procedures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Failure to design a documented, ongoing stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm failed to perform routine stability testing to demonstrate that the quality attributes of your APIs remain acceptable throughout the labeled expiry period. For example, your firm did not provide sufficient stability test data for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or other APIs manufactured at your facility.\u003C\u002Fp>\u003Cp>Without an appropriate stability program, you lack adequate scientific evidence to support that your APIs meet established specifications and retain their quality attributes throughout their labeled expiry.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective risk assessment showing how you will ensure that marketed APIs meet stability specifications throughout their shelf life.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include but should not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each API in its marketed container\u002Fclosure system before distribution is permitted\u003Cbr>o An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o A detailed definition of the specific attributes to be tested at each station (time point)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Failure to demonstrate that water used in the manufacture of your API is suitable for its intended use.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you failed to demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system is adequately monitored to ensure that it consistently produces water suitable for use in the manufacture of APIs intended for further processing into sterile drug products.\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system must be adequately designed and properly maintained to minimize and control the potential for contamination. It must be suitable for its intended use and routinely tested at an adequate frequency to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A procedure for monitoring your water system that specifies routine microbial testing of water to ensure its acceptability for use in each lot of APIs produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert levels for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring to ensure that the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003Cli>Test methods, water-analysis frequency, diagrams of the water system, and the location of all sampling points.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Additional API CGMP Guidance\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. \u003Cem>See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered from your firm for import into the United States on Import Alert 66-40 on January 30, 2026.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA’s continuing to refuse admission of articles manufactured at Hangzhou Yiqi Biotechnology Co., Ltd, No. 66 Xixiang Road, Puyan Street, Hangzhou, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3935145155 and ATTN: Chhaya Shetty.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-66\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jack Chai\n\nRecipient Title\n\nGeneral Manager\n\nHangzhou Yiqi Biotechnology Co., Ltd\n\nRoom 204, Building 3, No. 66 Xixiang Road, Puyan Street\n\nHangzhou Shi\n\nZhejiang Sheng, 310018\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-66\nApril 15, 2026\nDear Mr. Chai:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our June 16, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Hangzhou Yiqi Biotechnology Co., Ltd, FEI 3035145155, at Room 204, Building 3, No. 66 Xixiang Road, Puyan Street, Hangzhou, Zhejiang 310018, China.\nThis Warning Letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for APIs.\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant deviations were observed including, but not limited to, the following:\n1. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.\nBased on the records and information you provided, your firm failed to conduct process validation for the (b)(4) APIs manufactured at your facility. These APIs are for use in further processing to produce sterile drug products and for pharmaceutical compounding operations.\nProcess validation evaluates the soundness of design and state of control of a process throughout its life cycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nWithout adequate process validation, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA’s guidance for industry Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate process performance qualification for each of your marketed APIs.\nAlso provide a risk assessment and any follow up actions to be taken for the distributed APIs produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n2. Failure to validate and verify the suitability of analytical methods.\nBased on the records and information you provided, your firm failed to perform test method validation or verification for each test method used for drugs distributed to the United States.\nTest methods must be validated to show that they are suitable for their intended use or verified to show at least equivalence with United States Pharmacopeia (USP) compendial methods. Method validation and verification are necessary to support reliable determinations of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that the data provided to customers were an accurate reflection of pharmaceutical product quality and safety.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial test methods and specifications used to analyze each lot of your APIs before making a lot of disposition decisions, and the associated written procedures.\n3. Failure to design a documented, ongoing stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\nBased on the records and information you provided, your firm failed to perform routine stability testing to demonstrate that the quality attributes of your APIs remain acceptable throughout the labeled expiry period. For example, your firm did not provide sufficient stability test data for (b)(4), or other APIs manufactured at your facility.\nWithout an appropriate stability program, you lack adequate scientific evidence to support that your APIs meet established specifications and retain their quality attributes throughout their labeled expiry.\nIn response to this letter, provide:\nA retrospective risk assessment showing how you will ensure that marketed APIs meet stability specifications throughout their shelf life.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include but should not be limited to:\no Stability indicating methods\no Stability studies for each API in its marketed container\u002Fclosure system before distribution is permitted\no An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid\no A detailed definition of the specific attributes to be tested at each station (time point)\no All procedures that describe these and other elements of your remediated stability program.\n4. Failure to demonstrate that water used in the manufacture of your API is suitable for its intended use.\nBased on the records and information you provided, you failed to demonstrate that your (b)(4) water system is adequately monitored to ensure that it consistently produces water suitable for use in the manufacture of APIs intended for further processing into sterile drug products.\nYour (b)(4) water system must be adequately designed and properly maintained to minimize and control the potential for contamination. It must be suitable for its intended use and routinely tested at an adequate frequency to ensure ongoing conformance with appropriate chemical and microbiological attributes.\nIn response to this letter, provide:\nA procedure for monitoring your water system that specifies routine microbial testing of water to ensure its acceptability for use in each lot of APIs produced by your firm.\nThe current action\u002Falert levels for total counts and objectionable organisms used for your (b)(4) Water system.\nA procedure governing your program for ongoing control, maintenance, and monitoring to ensure that the remediated system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\nTest methods, water-analysis frequency, diagrams of the water system, and the location of all sampling points.\nAdditional API CGMP Guidance\nFDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed all drugs and drug products offered from your firm for import into the United States on Import Alert 66-40 on January 30, 2026.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA’s continuing to refuse admission of articles manufactured at Hangzhou Yiqi Biotechnology Co., Ltd, No. 66 Xixiang Road, Puyan Street, Hangzhou, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), and are misbranded under section 502 of the FD&C Act, respectively.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3935145155 and ATTN: Chhaya Shetty.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Hangzhou Yiqi Biotechnology Co., Ltd","hangzhou-yiqi-biotechnology-co-ltd-720707-04152026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-yiqi-biotechnology-co-ltd-720707-04152026","2026-10-26T08:08:52.533347+00:00","Warning Letter","Issued","2026-05-19","720707","Drugs","Mr. Jack Chai","2026-08-19T04:41:17.242+00:00","VIA EMAIL WITH READ RECEIPT","320-26-66","2026-04-15",{"id":33,"raw":34,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":51,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1151,[35,36,37,11,38,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-18T05:00:00Z\">11\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-huiji-biotechnology-co-ltd-692844-11182024\">Hangzhou Huiji Biotechnology Co., Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-16\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Zhan Libin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hangzhou Huiji Biotechnology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 3 Shunshuiqiao Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Renhe Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yuhang Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hangzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>310012\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-16\u003C\u002Fp>\n\n\u003Cp>November 18, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Libin:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 4, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Hangzhou Huiji Biotechnology Co., Ltd., FEI 3010461961, at No. 3 Shunshuiqiao Road, Renhe Street, Yuhang District, Hangzhou, Zhejiang.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>704(a)(4) Request for Records and Related CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures OTC drug products, including gel hand sanitizers containing ethyl alcohol. Based on the records and information you provided, you did not demonstrate that you adequately tested the identity of incoming components used in the manufacture of your drug products. For example, in your response, you state that you do not verify the identity of each shipment of drug ingredients prior to use in manufacturing. Additionally, you state that you do not utilize appropriate raw material tests described in USP, including the limit tests for DEG\u002FEG and methanol, despite your records indicating that you manufacture products containing glycerin and ethanol.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Information provided indicates that you failed to adequately test each shipment of each lot of glycerin for identity, a component at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. We note that glycerin is an ingredient used in your hand sanitizer drug products. Identity testing for glycerin and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Ethanol\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test your incoming ethanol, which is used as an active ingredient in your hand sanitizer, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that your components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate that you adequately tested your finished drug products for the identity and strength of the active ingredient, ethanol prior to release and distribution. For example, the “content of ethanol solutes” test procedure that you provided is not an appropriate laboratory determination of the identity and strength of your ethanol active ingredient. Additionally, you did not demonstrate the suitability of this test procedure per 21 CFR 211.165(e).\u003C\u002Fp>\n\n\u003Cp>Testing is an essential part of CGMP to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided, demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. For example, your QU failed to ensure that appropriate batch production records were used during the manufacturing of your drug products. Your QU also failed to ensure that adequate stability data supported the expiry of your drug products. In addition, your QU failed to ensure that your water system used in the manufacture of your OTC hand sanitizers, is appropriately designed and monitored in light of its intended use.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, we note that some of the drug products you manufacture may also be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. Under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded. Further, your facility may be subject to requirements of the Modernization of Cosmetic Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulationact-2022-mocra.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on November 15, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Hangzhou Huiji Biotechnology Co., Ltd., No. 3 Shunshuiqiao Road, Renhe Street, Yuhang District, Hangzhou Zhejiang, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017005720 and ATTN: Daniel W. Brisker.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nJames H Liao\u003Cbr>\nPrincipal\u003Cbr>\nApax International Inc.\u003Cbr>\njames@sino2us.com\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-16\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Zhan Libin\n\nRecipient Title\n\nGeneral Manager\n\nHangzhou Huiji Biotechnology Co., Ltd.\n\nNo. 3 Shunshuiqiao Road\n\nRenhe Street\n\nYuhang Qu\n\nHangzhou Shi\n\nZhejiang Sheng, 310012\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-16\n\nNovember 18, 2024\n\nDear Mr. Libin:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 4, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Hangzhou Huiji Biotechnology Co., Ltd., FEI 3010461961, at No. 3 Shunshuiqiao Road, Renhe Street, Yuhang District, Hangzhou, Zhejiang.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\n704(a)(4) Request for Records and Related CGMP Violations\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYour firm manufactures OTC drug products, including gel hand sanitizers containing ethyl alcohol. Based on the records and information you provided, you did not demonstrate that you adequately tested the identity of incoming components used in the manufacture of your drug products. For example, in your response, you state that you do not verify the identity of each shipment of drug ingredients prior to use in manufacturing. Additionally, you state that you do not utilize appropriate raw material tests described in USP, including the limit tests for DEG\u002FEG and methanol, despite your records indicating that you manufacture products containing glycerin and ethanol.\n\nGlycerin\n\nInformation provided indicates that you failed to adequately test each shipment of each lot of glycerin for identity, a component at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. We note that glycerin is an ingredient used in your hand sanitizer drug products. Identity testing for glycerin and certain other high-risk drug components1 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nEthanol\n\nYou failed to adequately test your incoming ethanol, which is used as an active ingredient in your hand sanitizer, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nWithout adequate testing, you do not have scientific evidence that your components conform to appropriate specifications prior to use in the manufacture of your drug products.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nBased on the records and information you provided, you did not demonstrate that you adequately tested your finished drug products for the identity and strength of the active ingredient, ethanol prior to release and distribution. For example, the “content of ethanol solutes” test procedure that you provided is not an appropriate laboratory determination of the identity and strength of your ethanol active ingredient. Additionally, you did not demonstrate the suitability of this test procedure per 21 CFR 211.165(e).\n\nTesting is an essential part of CGMP to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\n3. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided, demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. For example, your QU failed to ensure that appropriate batch production records were used during the manufacturing of your drug products. Your QU also failed to ensure that adequate stability data supported the expiry of your drug products. In addition, your QU failed to ensure that your water system used in the manufacture of your OTC hand sanitizers, is appropriately designed and monitored in light of its intended use.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions.\n\nCosmetics Manufactured for Distribution in the United States\n\nIn addition, we note that some of the drug products you manufacture may also be regulated as cosmetics, as defined in section 201(i) of the FD&C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. Under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded. Further, your facility may be subject to requirements of the Modernization of Cosmetic Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulationact-2022-mocra.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on November 15, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Hangzhou Huiji Biotechnology Co., Ltd., No. 3 Shunshuiqiao Road, Renhe Street, Yuhang District, Hangzhou Zhejiang, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017005720 and ATTN: Daniel W. Brisker.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCc:\n\nRegistered U.S. Agent\n\nJames H Liao\n\nPrincipal\n\nApax International Inc.\n\njames@sino2us.com\n\n_____________________\n\n1 Components with higher risk of DEG or EG contamination compared to other drug components.","Hangzhou Huiji Biotechnology Co., Ltd.","hangzhou-huiji-biotechnology-co-ltd-692844-11182024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-huiji-biotechnology-co-ltd-692844-11182024","2026-10-26T08:08:52.48141+00:00","2024-11-26","692844","Mr. Zhan Libin","2026-08-19T18:13:32.694+00:00","VIA UPS","320-25-16","2024-11-18",{"id":54,"raw":55,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":43,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":59,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":74,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},1204,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2024-10-22T13:20:00Z\">10\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-01T04:00:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famnio-technology-llc-646460-10012024\">Amnio Technology, LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 24-646460\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Merrill B. Stromer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Amnio Technology, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>22510 N. 18th Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85027-1363\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 1, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CBER 24-646460\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nDear Dr. Stromer:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Amnio Technology, LLC, located at 22510 N. 18th Drive, Phoenix, AZ 85027, conducted between August 15, 2022, and August 29, 2022, and your storage and distribution facility, located at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, conducted between August 17, 2022, and August 29, 2022, the United States Food and Drug Administration (FDA) documented your manufacture of an amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, and an amniotic fluid derived product, PalinGen® InovōFlo® (hereinafter, your products). You have distributed your products to third-party distributors, hospitals, and medical clinics throughout the United States.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your products are intended for injection and purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during, and\u002For after the inspection, including information from your contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reflect that your products are intended for use in the cure, treatment or prevention of diseases or conditions, such as wound healing and\u002For are intended to affect the structure or function of the body. For example, your promotional materials for PalinGen Flow state, “PalinGen Flow contain[s] key growth factors, cytokines, amino acids… hyaluronic acid, extracellular matrix proteins and cellular components recognized as intrinsic to the complex wound healing process,” and “Amniotic tissue is a rich source of various biologically active factors involved in tissue regeneration and wound healing with reported anti-inflammatory, anti-bacterial, re-epithelialization and anti-fibrotic properties.” Your promotional materials for PalinGen InovoFLo state, “Amniotic fluid possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications.”\u003C\u002Fp>\n\n\u003Cp>As a result, your products are drugs as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)(1)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Because PalinGen® Flow® contains amniotic membrane, in addition to being a drug and biological product, it is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, and are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of the materials described above, Amnio Technology, LLC does not qualify for any exception in 21 CFR 1271.15, and PalinGen® Flow® fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, PalinGen® Flow® is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>For example, PalinGen® Flow® fails to meet the minimal manipulation criterion set forth in section 1271.10(a)(1) and defined for structural tissue in section 1271.3(f)(1). During the manufacturing process for PalinGen® Flow®, amniotic membrane is processed \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a flowable form that can be administered by injection. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength, and elasticity.\u003C\u002Fp>\n\n\u003Cp>PalinGen® Flow® also fails to meet other criteria set forth in 21 CFR 1271.10(a). For example, PalinGen® Flow® fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” PalinGen® Flow® is not intended solely to perform the same basic function or functions of amniotic membrane in the recipient as in the donor (such as serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero). Rather, PalinGen® Flow® is intended, for example, for use in wound healing and tissue regeneration, which are not homologous uses of amniotic membrane as defined in 21 CFR 1271.3(c).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>PalinGen® InovōFlo® is not an HCT\u002FP. The definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted body fluids, such as amniotic fluid, are not considered HCT\u002FPs. Because PalinGen® InovōFlo® meets the definition of a drug under section 201(g) of the FD&amp;C Act and a biological product under section 351(i) of the PHS Act, your product is regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval.\u003C\u002Fp>\n\n\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312].\u003C\u002Fp>\n\n\u003Cp>Neither PalinGen® Flow® nor PalinGen® InovōFlo® are the subject of an approved BLA or an approved application under section 505(a) of the FD&amp;C Act. Since \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Amnio Technology, LLC \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>However, FDA’s inspection documented your distribution of PalinGen® Flow® for human use outside of a clinical investigation. Therefore, you are not exempt from the requirement to have an approved BLA or an approved application under section 505(a) in effect for PalinGen Flow. Further,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> PalinGen InovoFlo. Based on our review these products are unapproved new drugs, and your firm’s introduction or delivery for introduction of products into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act and section 351(a)(1) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (FDA-483), which described a number of significant CGMP deviations applicable to your products. These deficiencies include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. \u003Cstrong>Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm did not validate the manufacturing processes for PalinGen® Flow® or PalinGen® InovōFlo® with respect to identity, strength, quality, and purity.Your firm’s validation protocol is insufficient as it does not include supporting data demonstrating that your firm’s manufacturing process can consistently yield expected product characteristics.. Your firm distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of PalinGen® Flow® and approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of PalinGen® InovFlo® since January 2020 to August 2022. These units were distributed without process validation for these products.\u003C\u002Fp>\n\n\u003Cp>2. \u003Cstrong>Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. \u003C\u002Fstrong>Specifically, your firm has assigned a two-year expiration date to your products without adequate data demonstrating the stability characteristics of the products. For example, in your study protocol for PalinGen® Flow® under PROT-ENG-148, only assessed \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and did not include tests for sterility.\u003C\u002Fp>\n\n\u003Cp>3. \u003Cstrong>Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)].\u003C\u002Fstrong> For example, the report for consumer complaint CC-000159 related to PalinGen® Flow® indicated that the incident involved a communicable disease and required medical\u002Fsurgical intervention; however, you did not report this event to FDA within 15 days, as required by your written complaint procedure.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letters dated September 16, 2022, June 7, 2023, and December 20, 2023, which respond to the FDA-483. In your response, you represent that you have corrected the deficiencies documented on the FDA-483. However, your responses and the corrective actions described are not adequate to address our concerns. For example, in your response, you reference a validation protocol completed for PalinGen® Flow; however, you failed to provide supporting data to demonstrate that your manufacturing process can consistently yield product that meets established product specifications.\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address the inventory you still have at your facility and your specific plans for the disposition of this product inventory. Nor do you describe actions you have taken or plan to take to address the impact of the above-noted deficiencies on your products that you distributed.\u003C\u002Fp>\n\n\u003Cp>Your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA statutory and regulatory requirements that cover such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR parts 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483 are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We also have concerns regarding your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized amniotic fluid derived product, ProMatrX ACF®. Based on our review, this product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. It is also either a drug under section 201(g) of the FD&amp;C Act or a device under section 201(h) of the FD&amp;C Act. To lawfully market a biological product, either a valid biologics license or, as applicable, an appropriate device premarket authorization must be in effect. If you would like more information on which pathway is appropriate for this product, please contact us.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You manufacture an amniotic membrane derived product for private label customers using \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process used for Palingen Flow under product names including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, ASGFluid, Cell-ECT, Gryphon Amnio Flow, SXFluid, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The instructions for use are the same as those for PalinGen Flow. You also manufacture an amniotic membrane and amniotic fluid derived product for private label customers using the same manufacturing process used for PalinGen InovoFlo under the product name \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The instructions for use are the same as those for PalinGen InovoFlo.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, fails to meet the criterion at 21 CFR 1271.10(a)(1) and also fails to meet the criterion at 21 CFR 1271.10(a)(2), this letter does not address whether this product meets the criteria at 21 CFR 1271.10(a)(3) or (a)(4).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nCBER 24-646460\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMerrill B. Stromer\n\nRecipient Title\n\nChairman\n\nAmnio Technology, LLC\n\n22510 N. 18th Drive\n\nPhoenix, AZ 85027-1363\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nOctober 1, 2024\n\nCBER 24-646460\n\nDear Dr. Stromer:\n\nDuring an inspection of your firm, Amnio Technology, LLC, located at 22510 N. 18th Drive, Phoenix, AZ 85027, conducted between August 15, 2022, and August 29, 2022, and your storage and distribution facility, located at (b)(4), conducted between August 17, 2022, and August 29, 2022, the United States Food and Drug Administration (FDA) documented your manufacture of an amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, and an amniotic fluid derived product, PalinGen® InovōFlo® (hereinafter, your products). You have distributed your products to third-party distributors, hospitals, and medical clinics throughout the United States.1 Your products are intended for injection and purported to be sterile.\n\nInformation and records gathered prior to, during, and\u002For after the inspection, including information from your contract manufacturer, (b)(4), reflect that your products are intended for use in the cure, treatment or prevention of diseases or conditions, such as wound healing and\u002For are intended to affect the structure or function of the body. For example, your promotional materials for PalinGen Flow state, “PalinGen Flow contain[s] key growth factors, cytokines, amino acids… hyaluronic acid, extracellular matrix proteins and cellular components recognized as intrinsic to the complex wound healing process,” and “Amniotic tissue is a rich source of various biologically active factors involved in tissue regeneration and wound healing with reported anti-inflammatory, anti-bacterial, re-epithelialization and anti-fibrotic properties.” Your promotional materials for PalinGen InovoFLo state, “Amniotic fluid possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications.”\n\nAs a result, your products are drugs as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)(1)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nBecause PalinGen® Flow® contains amniotic membrane, in addition to being a drug and biological product, it is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, and are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of the materials described above, Amnio Technology, LLC does not qualify for any exception in 21 CFR 1271.15, and PalinGen® Flow® fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, PalinGen® Flow® is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nFor example, PalinGen® Flow® fails to meet the minimal manipulation criterion set forth in section 1271.10(a)(1) and defined for structural tissue in section 1271.3(f)(1). During the manufacturing process for PalinGen® Flow®, amniotic membrane is processed (b)(4) to a flowable form that can be administered by injection. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength, and elasticity.\n\nPalinGen® Flow® also fails to meet other criteria set forth in 21 CFR 1271.10(a). For example, PalinGen® Flow® fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” PalinGen® Flow® is not intended solely to perform the same basic function or functions of amniotic membrane in the recipient as in the donor (such as serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero). Rather, PalinGen® Flow® is intended, for example, for use in wound healing and tissue regeneration, which are not homologous uses of amniotic membrane as defined in 21 CFR 1271.3(c).2\n\nPalinGen® InovōFlo® is not an HCT\u002FP. The definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted body fluids, such as amniotic fluid, are not considered HCT\u002FPs. Because PalinGen® InovōFlo® meets the definition of a drug under section 201(g) of the FD&C Act and a biological product under section 351(i) of the PHS Act, your product is regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval.\n\nTo lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312].\n\nNeither PalinGen® Flow® nor PalinGen® InovōFlo® are the subject of an approved BLA or an approved application under section 505(a) of the FD&C Act. Since (b)(4), Amnio Technology, LLC (b)(4) However, FDA’s inspection documented your distribution of PalinGen® Flow® for human use outside of a clinical investigation. Therefore, you are not exempt from the requirement to have an approved BLA or an approved application under section 505(a) in effect for PalinGen Flow. Further, (b)(4) PalinGen InovoFlo. Based on our review these products are unapproved new drugs, and your firm’s introduction or delivery for introduction of products into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act and section 351(a)(1) of the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (FDA-483), which described a number of significant CGMP deviations applicable to your products. These deficiencies include, but are not limited to, the following:\n\n1. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, your firm did not validate the manufacturing processes for PalinGen® Flow® or PalinGen® InovōFlo® with respect to identity, strength, quality, and purity.Your firm’s validation protocol is insufficient as it does not include supporting data demonstrating that your firm’s manufacturing process can consistently yield expected product characteristics.. Your firm distributed approximately (b)(4) units of PalinGen® Flow® and approximately (b)(4) units of PalinGen® InovFlo® since January 2020 to August 2022. These units were distributed without process validation for these products.\n\n2. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, your firm has assigned a two-year expiration date to your products without adequate data demonstrating the stability characteristics of the products. For example, in your study protocol for PalinGen® Flow® under PROT-ENG-148, only assessed (b)(4) and (b)(4) and did not include tests for sterility.\n\n3. Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)]. For example, the report for consumer complaint CC-000159 related to PalinGen® Flow® indicated that the incident involved a communicable disease and required medical\u002Fsurgical intervention; however, you did not report this event to FDA within 15 days, as required by your written complaint procedure.\n\nWe acknowledge receipt of your letters dated September 16, 2022, June 7, 2023, and December 20, 2023, which respond to the FDA-483. In your response, you represent that you have corrected the deficiencies documented on the FDA-483. However, your responses and the corrective actions described are not adequate to address our concerns. For example, in your response, you reference a validation protocol completed for PalinGen® Flow; however, you failed to provide supporting data to demonstrate that your manufacturing process can consistently yield product that meets established product specifications.\n\nYour response also does not adequately address the inventory you still have at your facility and your specific plans for the disposition of this product inventory. Nor do you describe actions you have taken or plan to take to address the impact of the above-noted deficiencies on your products that you distributed.\n\nYour response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA statutory and regulatory requirements that cover such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR parts 312].\n\nNeither this letter nor the observations noted on the FDA-483 are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe also have concerns regarding your (b)(4) sterilized amniotic fluid derived product, ProMatrX ACF®. Based on our review, this product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. It is also either a drug under section 201(g) of the FD&C Act or a device under section 201(h) of the FD&C Act. To lawfully market a biological product, either a valid biologics license or, as applicable, an appropriate device premarket authorization must be in effect. If you would like more information on which pathway is appropriate for this product, please contact us.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\nCc:\n\n(b)(4)\n\n_________________________\n\n1 You manufacture an amniotic membrane derived product for private label customers using (b)(4) manufacturing process used for Palingen Flow under product names including (b)(4), ASGFluid, Cell-ECT, Gryphon Amnio Flow, SXFluid, and (b)(4). The instructions for use are the same as those for PalinGen Flow. You also manufacture an amniotic membrane and amniotic fluid derived product for private label customers using the same manufacturing process used for PalinGen InovoFlo under the product name (b)(4). The instructions for use are the same as those for PalinGen InovoFlo.\n\n2 Because your amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, fails to meet the criterion at 21 CFR 1271.10(a)(1) and also fails to meet the criterion at 21 CFR 1271.10(a)(2), this letter does not address whether this product meets the criteria at 21 CFR 1271.10(a)(3) or (a)(4).","Amnio Technology, LLC","amnio-technology-llc-646460-10012024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famnio-technology-llc-646460-10012024","2026-10-26T08:07:55.44972+00:00","2024-10-22","646460","Biologics","Merrill B. Stromer","2026-08-19T21:55:18.541+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","CBER 24-646460","2024-10-01",{"id":77,"raw":78,"subject":82,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":18,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},238,[79,80,81,11,82,13,13,13],"\u003Ctime datetime=\"2026-04-07T04:00:00Z\">04\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangzhou-huli-technology-co-ltd-dba-fantasy-face-722228-03312026\">Guangzhou Huli Technology Co., Ltd. dba Fantasy Face\u003C\u002Fa>","Unapproved New Drugs Sold Over the Internet","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Haijie Long\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Guangzhou Huli Technology Co., Ltd. dba Fantasy Face\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>933 W 32nd St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chicago\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60608\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lsj20250509@163.com\"> lsj20250509@163.com   \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 31, 2026\u003C\u002Fp>\u003Cp>RE: 722228\u003C\u002Fp>\u003Cp>Haijie Long:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your eBay store at https:\u002F\u002Fwww.ebay.com\u002Fstr\u002Ffantasyface in December 2025. The FDA has observed that your eBay store offers “Googeer GLP-1 Weight Control Oral Solution” for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>Based on a review of your eBay store, your “Googeer GLP-1 Weight Control Oral Solution” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from your product labeling, including on your eBay store, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Googeer GLP-1 Weight Control Oral Solution\u003C\u002Fu>\u003Cbr>On the your eBay store webpage https:\u002F\u002Fwww.ebay.com\u002Fitm\u002F357972658414?itmmeta=01KBR20V0X11QS0M7FX9DMNAJ9&amp;hash=item5358d548ee:g:XG0AAeSwfq5osANH:\u003C\u002Fp>\u003Cul>\u003Cli>“Metabolism Support . . . Weight management Blood Sugar Balance”\u003C\u002Fli>\u003Cli>“Ideal Body Shaping helps to shape a slim body.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your “Googeer GLP-1 Weight Control Oral Solution” product is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in the labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this product. Accordingly, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “722228” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:&nbsp;\u003C\u002Fp>\u003Cp>Mike Carson\u003Cbr>Regulatory Policy Group\u003Cbr>eBay, Inc.\u003Cbr>2025 Hamilton Avenue\u003Cbr>San Jose, California 95125\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nHaijie Long\n\nGuangzhou Huli Technology Co., Ltd. dba Fantasy Face\n\n933 W 32nd St\n\nChicago, IL 60608\n\nUnited States\n\nlsj20250509@163.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 31, 2026\nRE: 722228\nHaijie Long:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your eBay store at https:\u002F\u002Fwww.ebay.com\u002Fstr\u002Ffantasyface in December 2025. The FDA has observed that your eBay store offers “Googeer GLP-1 Weight Control Oral Solution” for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nBased on a review of your eBay store, your “Googeer GLP-1 Weight Control Oral Solution” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\nExamples from your product labeling, including on your eBay store, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\nGoogeer GLP-1 Weight Control Oral Solution\nOn the your eBay store webpage https:\u002F\u002Fwww.ebay.com\u002Fitm\u002F357972658414?itmmeta=01KBR20V0X11QS0M7FX9DMNAJ9&hash=item5358d548ee:g:XG0AAeSwfq5osANH:\n“Metabolism Support . . . Weight management Blood Sugar Balance”\n“Ideal Body Shaping helps to shape a slim body.”\nYour “Googeer GLP-1 Weight Control Oral Solution” product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in the labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product. Accordingly, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “722228” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\ncc:\nMike Carson\nRegulatory Policy Group\neBay, Inc.\n2025 Hamilton Avenue\nSan Jose, California 95125","Guangzhou Huli Technology Co., Ltd. dba Fantasy Face","guangzhou-huli-technology-co-ltd-dba-fantasy-face-722228-03312026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangzhou-huli-technology-co-ltd-dba-fantasy-face-722228-03312026","2026-10-26T08:08:51.370831+00:00","2026-04-07","722228","Haijie Long","2026-08-19T04:48:56.441+00:00","Via Email","2026-03-31",{"id":96,"raw":97,"subject":102,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":108,"fei_number":19,"letter_url":109,"updated_at":110,"action_type":22,"case_status":111,"posted_date":112,"marcs_cms_no":113,"product_type":114,"closeout_date":115,"issuing_office":101,"recipient_name":116,"body_fetched_at":117,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":118,"medical_device_id":19,"response_letter_date":19},2051,[98,99,100,101,102,13,103,13],"\u003Ctime datetime=\"2023-06-20T13:20:00Z\">06\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-12T04:00:00Z\">06\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-06122023\">Vitang Technology LLC\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-07232024\">\u003Ctime datetime=\"2024-07-31T04:00:00Z\">07\u002F31\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ronald Jiang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vitang Technology LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14662 Franklin Ave Ste H\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tustin\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92780-7224\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ron@vitangtechnology.com\"> ron@vitangtechnology.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER \u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CMS # 653455\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 12, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jiang:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Vitang Technology LLC. (Vitang or “the firm”), located in Tustin, CA on January 24, 2023 through January 31, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of The UniSmile Clear Aligner, a Class II dental aligner, cleared under 510(k) K191837and marketed as both the “UniSmile Clear Aligner System” and “2usmiles” on your firm’s websites. For example, your website (https:\u002F\u002Funismile.us\u002F) promotes the device name Unismile. Additionally, your website (https:\u002F\u002Fwww.2usmiles.com\u002F) promotes the device name 2usmiles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the UniSmile Clear Aligner System is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>We received your response, dated February 20, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded and\u002For Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm currently holds a 510(k) clearance for the “UniSmile Clear Aligner System.” This device was cleared on January 30, 2020, under K191837 for, among other things, treatment of tooth malocclusion in patients with permanent dentition by way of continuous gentle force. Your 510(k) summary dated January 29, 2020 states that “Software is used to design treatment plans. The software used with UniSmile Clear Aligner System is the Orchestrate 3D (K181112) software, version OrthoRx 4”.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm made changes to the device without submission of a new 510(k). On November 26, 2019 you changed from using the cleared Orchestrate 3D to the non-cleared iRok OrthoRx 4.0 for the development of the treatment plans for your UniSmile Clear Aligner System. You indicated that you performed verification and validation activities on iRok OrthoRx 4.0 and concluded that this software is “similar in designing clear aligner treatment plans” as Orchestrate 3D (K181112). However, note that verification and validation requirements apply for all devices subject to 21 CFR 820.30, and must be conducted regardless of whether submission of a new 510(k) is required. A change in orthodontic treatment planning software is a change that could significantly affect the safety and effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Specifically, a change from Orchestrate 3D to iRok OrthoRx 4.0 has the potential to affect the proposed treatment protocol as well as the dimensions, configurations, and applied forces of the UniSmile Clear Aligners, and affect the clinical outcome. Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified UniSmile Clear Aligner System. You did not submit any new 510(k) for the referenced modification to the UniSmile Clear Aligner System.\u003C\u002Fp>\n\n\u003Cp>Therefore, your devices are misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). Your devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the UniSmile Clear Aligner System is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198.\u003C\u002Fp>\n\n\u003Cp>Specifically, our inspection revealed that your firm has failed to establish and maintain procedures for (1) determining whether a complaint is reportable to the FDA under part 803, (2) investigating the possible failure of a device to meet any of its specifications, and (3) receiving complaints outside of your firm's complaint management system, including oral complaints. Instead, your procedure,\u003Cem> Customer complaints and refinements\u003C\u002Fem>, is used to only to provide refinement services, (e.g., rescans). For example, 11 out of 13 complaint records reviewed during our inspection did not include an evaluation for MDR reportability nor an evaluation to determine if an investigation was necessary. In addition, you did not perform an investigation into reports of broken aligners.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response, and it is inadequate. Although you stated that you recognize that your procedure lacks specific steps to report death or serious injuries, and that you will review and update procedures to comply with MDR reporting requirements within 6 weeks of your response and conduct training, you have not provided evidence of the corrective and preventive actions. Further, your response is also inadequate because it did not address corrective actions that you have taken or plan to take to establish procedures for investigating the possible failure of a device to meet any of its specifications or receiving complaints outside of your firm's complaint management system, including oral complaints.\u003C\u002Fp>\n\n\u003Cp>2. Failure to validate software used as part of the quality system for its intended use according to an established protocol, as required by 21 CFR 820.70(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, you failed to validate your complaint handling system software. Your Ruby on Rails server-side web application framework, using the programming language Ruby and found at unismile.us, is used to maintain complaint files. However, your firm has failed to validate the software for its intended use.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. In your response, your firm stated that your complaint handling system has been in use for a few years and has “proven to be effective.” However, your firm has not provided evidence of the effectiveness of this complaint handling system. Additionally, your firm stated that you initiated an action plan to validate the complaint handling system. You committed to generate a software validation report, approach, testing methodology, and results of the validation within 6 weeks of your response to FDA. You have not provided a response with evidence of the corrective and preventive actions relevant to the complaint handling system effectiveness.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including evaluation of suppliers, contractors, and consultants, as required by 21 CFR 820.50(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, you are not defining the type and extent of control to be exercised over supplier services. When our investigator asked for an evaluation of your firm’s suppliers, you only provided a Manufacturing and Supply Agreement with Xi’an Henghui Technologies Co., Ltd. The August 27, 2021, manufacturing agreement with Henghui, the Chinese contract manufacturer and supplier for the uncleared software you use in the design of the dental aligners, does not identify the roles and responsibilities of both companies. Henghui has contract manufactured your devices since 2019.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you conducted comprehensive inspections of your critical supplier, Henghui, including site visits, and documented the results. You stated to look at an Attachment A. However, the response did not contain an Attachment A. Further, all supporting documents in the response are in Chinese and cannot be reviewed or assessed. You stated that you plan to review the supplier evaluation process and update necessary documents as soon as possible, and conduct auditing of all suppliers, within 12 weeks of the response. You have not provided a response with evidence of the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR § 820.75(b), and failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, including the validation of major equipment, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your \u003Cem>Validation of Process\u003C\u002Fem> procedure refers to “approval of equipment” but does not address equipment qualification to show that equipment is appropriately designed, constructed, placed, and installed. You stated during the inspection that you have documents in Chinese from the supplier that show the installation and qualifications of your 3D printer. However, since they were not in English, we were unable to verify this statement nor if your firm validated the 3D printing process used to manufacture the UniSmile Clear Aligner System. In addition, your firm’s General Manager and Engineering Manager stated that your firm documents the installation of the printers and the operational and performance qualification in the HeyGears Ultracraft A2D Quasi-Industrial Grade DLP 3D Printer operation manual when an installation occurs. However, that manual does not indicate when the qualification occurred or include evidence that it was performed.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that your response is inadequate. Your firm has not provided a procedure that addresses major equipment qualification or process validation for your 3D printing process. You stated that you will complete the necessary updates to the equipment qualification documents for all equipment within 12 weeks of the response and conduct training. We request that you provide evidence that your 3D printing process has been qualified and validated.\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish and maintain procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, the Equipment Calibration List in your firm’s \u003Cem>Control of Monitoring and Measuring Equipment’s\u003C\u002Fem> procedure states that the 3D Printer should be calibrated monthly, but your firm could only provide a record of quarterly maintenance. You are not documenting the next calibration due date for your 3D printers used in the manufacture of dental aligners. Records are not readily available to the personnel using such equipment as you do not keep the records at the firm. Instead, your firm stated that they are kept with the 3D printer supplier\u002Fcalibrator.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that the equipment has been calibrated but, due to a manpower shortage, some of the records were not available. You also stated this was compounded by deficiencies in forms and procedures. You stated that you will review your forms and procedures relating to calibration and update as necessary within 10 weeks of the response. You have not provided calibration records to show all equipment was calibrated on the required schedule and have not provided a response with evidence of the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish procedures for device history records as required by 21 CFR 820.184.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm does not have a device history record (DHR) procedure. For example, a review of 11 out of 13 device history records (DHRs) for dental aligners did not include nor make reference to the primary identification label and labeling used for each production unit. In addition, the device history records do not contain any UDI information on its label or labeling. During our inspection, you stated that the procedure is being held at the supplier in China.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you reviewed Henghui’s procedures and quality documents and deemed them equivalent to your firm’s procedure in Attachment B. You stated that you can obtain documents from Henghui upon request and then referenced an Attachment C. Both attachments are in Chinese, and we are unable to review them. You stated that the DHR does not include or refer to the location of any UDI or UPC as you believed the devices were custom-made and exempt. In your response you stated that you plan to conduct a review and update of device history process procedures with 8 weeks of the response and provide guidance to all employees; and you will review and update shipping documentation within 4 weeks of the response and then conduct training. You stated that you will update your DHRs with regard to UDI\u002FUPC within 6 weeks of the response and provide training to employees.\u003C\u002Fp>\n\n\u003Cp>7. Failure to document the results and\u002For dates of management reviews as required by 21 CFR 820.20(c).\u003Cbr>\n\u003Cbr>\nSpecifically, you firm has no record of management reviews. Your \u003Cem>Quality Manual and Management Responsibility\u003C\u002Fem> documents both make references to the required conduct of management reviews. You provided a memo on 01\u002F30\u002F2023 that they have been conducted. However, it is generalized as to the topics covered and there are no dates of reviews documented.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate because it does not address this observation.\u003C\u002Fp>\n\n\u003Cp>8. Failure to document personnel training as required by 21 CFR 820.25(b).\u003C\u002Fp>\n\n\u003Cp>Your firm has failed to document training records. Specifically, you were unable to provide training records for General\u002FEngineering Manager and the CEO\u002FVice President of Operations\u002FHead of Shipment Tracking and Handling.\u003C\u002Fp>\n\n\u003Cp>However, your procedure that we did review indicates that new employees attend an orientation that includes training on the quality system, the quality policy, the importance of meeting regulatory, statutory and customer requirements, and the relevance and importance of their activities and how they contribute to the achievement of the quality objective. However, there is no documentation of this orientation.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate because it does not address your firm’s failure to document personnel training.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Representations that Create an Impression of FDA Approval\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The UniSmile Clear Aligner System is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because a representation on your website creates an impression of official approval of the device and is misleading. In addition, 21 CFR 807.97 states that any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. Your website contains such representations. Specifically, your website at https:\u002F\u002Fwww.2usmiles.com\u002Fwhy-2usmiles states: “FDA APPROVED.” and incorporates the FDA logo. Statements about having active status with the FDA, and display of the FDA logo near images of and information about the respective products, is misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>In addition, we offer the following comment:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>We note that we are unable to identify whether the device covered by the above-referenced 510(k) clearance is the same as the 2usmiles your firm is currently marketing. We request that you provide to us in writing with your firm’s basis for determining the 2usmiles is the same device described in K191837.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implantation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 653455 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u002FWest\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRonald Jiang\n\nRecipient Title\n\nOwner & CEO\n\nVitang Technology LLC\n\n14662 Franklin Ave Ste H\n\nTustin, CA 92780-7224\n\nUnited States\n\nron@vitangtechnology.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 653455\n\nJune 12, 2023\n\nDear Mr. Jiang:\n\nDuring an inspection of your firm, Vitang Technology LLC. (Vitang or “the firm”), located in Tustin, CA on January 24, 2023 through January 31, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of The UniSmile Clear Aligner, a Class II dental aligner, cleared under 510(k) K191837and marketed as both the “UniSmile Clear Aligner System” and “2usmiles” on your firm’s websites. For example, your website (https:\u002F\u002Funismile.us\u002F) promotes the device name Unismile. Additionally, your website (https:\u002F\u002Fwww.2usmiles.com\u002F) promotes the device name 2usmiles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the UniSmile Clear Aligner System is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nWe received your response, dated February 20, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\n\nMisbranded and\u002For Unapproved Device Violations\n\nOur inspection revealed that your firm currently holds a 510(k) clearance for the “UniSmile Clear Aligner System.” This device was cleared on January 30, 2020, under K191837 for, among other things, treatment of tooth malocclusion in patients with permanent dentition by way of continuous gentle force. Your 510(k) summary dated January 29, 2020 states that “Software is used to design treatment plans. The software used with UniSmile Clear Aligner System is the Orchestrate 3D (K181112) software, version OrthoRx 4”.\n\nOur inspection revealed that your firm made changes to the device without submission of a new 510(k). On November 26, 2019 you changed from using the cleared Orchestrate 3D to the non-cleared iRok OrthoRx 4.0 for the development of the treatment plans for your UniSmile Clear Aligner System. You indicated that you performed verification and validation activities on iRok OrthoRx 4.0 and concluded that this software is “similar in designing clear aligner treatment plans” as Orchestrate 3D (K181112). However, note that verification and validation requirements apply for all devices subject to 21 CFR 820.30, and must be conducted regardless of whether submission of a new 510(k) is required. A change in orthodontic treatment planning software is a change that could significantly affect the safety and effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Specifically, a change from Orchestrate 3D to iRok OrthoRx 4.0 has the potential to affect the proposed treatment protocol as well as the dimensions, configurations, and applied forces of the UniSmile Clear Aligners, and affect the clinical outcome. Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified UniSmile Clear Aligner System. You did not submit any new 510(k) for the referenced modification to the UniSmile Clear Aligner System.\n\nTherefore, your devices are misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). Your devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nQuality System Regulation (QSR) Violations\n\nOur inspection also revealed that the UniSmile Clear Aligner System is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198.\n\nSpecifically, our inspection revealed that your firm has failed to establish and maintain procedures for (1) determining whether a complaint is reportable to the FDA under part 803, (2) investigating the possible failure of a device to meet any of its specifications, and (3) receiving complaints outside of your firm's complaint management system, including oral complaints. Instead, your procedure, Customer complaints and refinements, is used to only to provide refinement services, (e.g., rescans). For example, 11 out of 13 complaint records reviewed during our inspection did not include an evaluation for MDR reportability nor an evaluation to determine if an investigation was necessary. In addition, you did not perform an investigation into reports of broken aligners.\n\nWe reviewed your firm’s response, and it is inadequate. Although you stated that you recognize that your procedure lacks specific steps to report death or serious injuries, and that you will review and update procedures to comply with MDR reporting requirements within 6 weeks of your response and conduct training, you have not provided evidence of the corrective and preventive actions. Further, your response is also inadequate because it did not address corrective actions that you have taken or plan to take to establish procedures for investigating the possible failure of a device to meet any of its specifications or receiving complaints outside of your firm's complaint management system, including oral complaints.\n\n2. Failure to validate software used as part of the quality system for its intended use according to an established protocol, as required by 21 CFR 820.70(i).\n\nSpecifically, you failed to validate your complaint handling system software. Your Ruby on Rails server-side web application framework, using the programming language Ruby and found at unismile.us, is used to maintain complaint files. However, your firm has failed to validate the software for its intended use.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. In your response, your firm stated that your complaint handling system has been in use for a few years and has “proven to be effective.” However, your firm has not provided evidence of the effectiveness of this complaint handling system. Additionally, your firm stated that you initiated an action plan to validate the complaint handling system. You committed to generate a software validation report, approach, testing methodology, and results of the validation within 6 weeks of your response to FDA. You have not provided a response with evidence of the corrective and preventive actions relevant to the complaint handling system effectiveness.\n\n3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including evaluation of suppliers, contractors, and consultants, as required by 21 CFR 820.50(a).\n\nSpecifically, you are not defining the type and extent of control to be exercised over supplier services. When our investigator asked for an evaluation of your firm’s suppliers, you only provided a Manufacturing and Supply Agreement with Xi’an Henghui Technologies Co., Ltd. The August 27, 2021, manufacturing agreement with Henghui, the Chinese contract manufacturer and supplier for the uncleared software you use in the design of the dental aligners, does not identify the roles and responsibilities of both companies. Henghui has contract manufactured your devices since 2019.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you conducted comprehensive inspections of your critical supplier, Henghui, including site visits, and documented the results. You stated to look at an Attachment A. However, the response did not contain an Attachment A. Further, all supporting documents in the response are in Chinese and cannot be reviewed or assessed. You stated that you plan to review the supplier evaluation process and update necessary documents as soon as possible, and conduct auditing of all suppliers, within 12 weeks of the response. You have not provided a response with evidence of the corrective and preventive actions.\n\n4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR § 820.75(b), and failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, including the validation of major equipment, as required by 21 CFR 820.75(a).\n\nSpecifically, your Validation of Process procedure refers to “approval of equipment” but does not address equipment qualification to show that equipment is appropriately designed, constructed, placed, and installed. You stated during the inspection that you have documents in Chinese from the supplier that show the installation and qualifications of your 3D printer. However, since they were not in English, we were unable to verify this statement nor if your firm validated the 3D printing process used to manufacture the UniSmile Clear Aligner System. In addition, your firm’s General Manager and Engineering Manager stated that your firm documents the installation of the printers and the operational and performance qualification in the HeyGears Ultracraft A2D Quasi-Industrial Grade DLP 3D Printer operation manual when an installation occurs. However, that manual does not indicate when the qualification occurred or include evidence that it was performed.\n\nWe reviewed your firm’s response and concluded that your response is inadequate. Your firm has not provided a procedure that addresses major equipment qualification or process validation for your 3D printing process. You stated that you will complete the necessary updates to the equipment qualification documents for all equipment within 12 weeks of the response and conduct training. We request that you provide evidence that your 3D printing process has been qualified and validated.\n\n5. Failure to adequately establish and maintain procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\n\nSpecifically, the Equipment Calibration List in your firm’s Control of Monitoring and Measuring Equipment’s procedure states that the 3D Printer should be calibrated monthly, but your firm could only provide a record of quarterly maintenance. You are not documenting the next calibration due date for your 3D printers used in the manufacture of dental aligners. Records are not readily available to the personnel using such equipment as you do not keep the records at the firm. Instead, your firm stated that they are kept with the 3D printer supplier\u002Fcalibrator.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that the equipment has been calibrated but, due to a manpower shortage, some of the records were not available. You also stated this was compounded by deficiencies in forms and procedures. You stated that you will review your forms and procedures relating to calibration and update as necessary within 10 weeks of the response. You have not provided calibration records to show all equipment was calibrated on the required schedule and have not provided a response with evidence of the corrective and preventive actions.\n\n6. Failure to establish procedures for device history records as required by 21 CFR 820.184.\n\nSpecifically, your firm does not have a device history record (DHR) procedure. For example, a review of 11 out of 13 device history records (DHRs) for dental aligners did not include nor make reference to the primary identification label and labeling used for each production unit. In addition, the device history records do not contain any UDI information on its label or labeling. During our inspection, you stated that the procedure is being held at the supplier in China.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you reviewed Henghui’s procedures and quality documents and deemed them equivalent to your firm’s procedure in Attachment B. You stated that you can obtain documents from Henghui upon request and then referenced an Attachment C. Both attachments are in Chinese, and we are unable to review them. You stated that the DHR does not include or refer to the location of any UDI or UPC as you believed the devices were custom-made and exempt. In your response you stated that you plan to conduct a review and update of device history process procedures with 8 weeks of the response and provide guidance to all employees; and you will review and update shipping documentation within 4 weeks of the response and then conduct training. You stated that you will update your DHRs with regard to UDI\u002FUPC within 6 weeks of the response and provide training to employees.\n\n7. Failure to document the results and\u002For dates of management reviews as required by 21 CFR 820.20(c).\n\nSpecifically, you firm has no record of management reviews. Your Quality Manual and Management Responsibility documents both make references to the required conduct of management reviews. You provided a memo on 01\u002F30\u002F2023 that they have been conducted. However, it is generalized as to the topics covered and there are no dates of reviews documented.\n\nYour firm’s response is inadequate because it does not address this observation.\n\n8. Failure to document personnel training as required by 21 CFR 820.25(b).\n\nYour firm has failed to document training records. Specifically, you were unable to provide training records for General\u002FEngineering Manager and the CEO\u002FVice President of Operations\u002FHead of Shipment Tracking and Handling.\n\nHowever, your procedure that we did review indicates that new employees attend an orientation that includes training on the quality system, the quality policy, the importance of meeting regulatory, statutory and customer requirements, and the relevance and importance of their activities and how they contribute to the achievement of the quality objective. However, there is no documentation of this orientation.\n\nYour firm’s response is inadequate because it does not address your firm’s failure to document personnel training.\n\nRepresentations that Create an Impression of FDA Approval\n\nThe UniSmile Clear Aligner System is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because a representation on your website creates an impression of official approval of the device and is misleading. In addition, 21 CFR 807.97 states that any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. Your website contains such representations. Specifically, your website at https:\u002F\u002Fwww.2usmiles.com\u002Fwhy-2usmiles states: “FDA APPROVED.” and incorporates the FDA logo. Statements about having active status with the FDA, and display of the FDA logo near images of and information about the respective products, is misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nIn addition, we offer the following comment:\n\nWe note that we are unable to identify whether the device covered by the above-referenced 510(k) clearance is the same as the 2usmiles your firm is currently marketing. We request that you provide to us in writing with your firm’s basis for determining the 2usmiles is the same device described in K191837.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implantation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 653455 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\u002FWest","Vitang Technology LLC","vitang-technology-llc-653455-06122023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-06122023","2026-10-26T08:10:28.614825+00:00","Closed Out","2023-06-20","653455","Medical Devices","2024-07-31","Ronald Jiang","2026-08-20T01:02:45.663+00:00","2023-06-12",{"id":120,"raw":121,"subject":38,"body_html":125,"body_text":126,"firm_name":127,"letter_id":128,"created_at":129,"fei_number":19,"letter_url":130,"updated_at":131,"action_type":22,"case_status":23,"posted_date":132,"marcs_cms_no":133,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":134,"body_fetched_at":135,"delivery_method":136,"recipient_title":19,"reference_number":137,"action_taken_date":138,"medical_device_id":19,"response_letter_date":19},908,[122,123,124,11,38,13,13,13],"\u003Ctime datetime=\"2025-05-13T04:00:00Z\">05\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-02T04:00:00Z\">04\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftaizhou-jingshang-cosmetics-technology-co-ltd-701945-04022025\">Taizhou Jingshang Cosmetics Technology Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-60\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Zheng Liang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Taizhou Jingshang Cosmetics Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>888 South Huanzhen Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hengie Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Luqiao Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Taizhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>318050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-60\u003C\u002Fp>\u003Cp>April 2, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Liang:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Taizhou Jingshang Cosmetics Technology Co., Ltd., FEI 3014244255, located at Luqiao District, Shanhoupan Village, Hengjie Town, Taizhou, Zhejiang Province, China, from November 18 to 21, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We have not received a response from your firm stating the specific actions you are taking to address the deficiencies identified during the inspection and cited on our Form FDA 483.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures \u003Cstrong>(b)(4)\u003C\u002Fstrong> over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. You have not demonstrated that you adequately test all incoming components for identity used in the manufacture of your OTC drug products. Additionally, you accepted the certificate of analyses from suppliers without verifying the information provided by your suppliers.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used as an active pharmaceutical ingredient, for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for identity, a component at high-risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. Identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and certain other high-risk drug components\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your laboratory records did not include complete data to support the analysis performed. For example, the electronic data generated by the gas chromatography system was not appropriately backed up to a separate storage location and appeared to have been deleted from the system. In addition, the paper records provided were illegible and lacked traceability to specific batches.\u003C\u002Fp>\u003Cp>Reliability of data is compromised when there is a failure to maintain complete records of the conditions and data associated with all tests. Furthermore, the lack of complete data compromises the quality unit’s (QU) ability to exercise its function of ensuring compliance to applicable standards.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish an adequate QU with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Appropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Appropriate assay test methods, procedures, or validation for testing of in-process and finished drug products (21 CFR 211.160(b)).\u003C\u002Fli>\u003Cli>Establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Performance of an appropriate periodic (at least annual) review of drug product production (21 CFR 211.180(e)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to cease production of all drugs at this facility.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. Should you resume manufacturing drugs, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Taizhou Jingshang Cosmetics Technology Co., Ltd., Shanhoupan Village, Hengjie Town, Luqiao District Taizhou, Zhejiang Province, China, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014244255 and ATTN: Christopher M. Jenner.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-60\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Zheng Liang\n\nRecipient Title\n\nGeneral Manager\n\nTaizhou Jingshang Cosmetics Technology Co., Ltd.\n\n888 South Huanzhen Road\n\nHengie Town\n\nLuqiao Qu\n\nTaizhou Shi\n\nZhejiang Sheng, 318050\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-60\nApril 2, 2025\nDear Mr. Liang:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Taizhou Jingshang Cosmetics Technology Co., Ltd., FEI 3014244255, located at Luqiao District, Shanhoupan Village, Hengjie Town, Taizhou, Zhejiang Province, China, from November 18 to 21, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe have not received a response from your firm stating the specific actions you are taking to address the deficiencies identified during the inspection and cited on our Form FDA 483.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\nCGMP Violations\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures (b)(4) over-the-counter (OTC) (b)(4) drug products. You have not demonstrated that you adequately test all incoming components for identity used in the manufacture of your OTC drug products. Additionally, you accepted the certificate of analyses from suppliers without verifying the information provided by your suppliers.\n(b)(4)\nYou failed to adequately test your incoming (b)(4), used as an active pharmaceutical ingredient, for (b)(4). The use of (b)(4) contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing (b)(4) at (b)(4)\n(b)(4)\nYou failed to adequately test each shipment of each lot of (b)(4) for identity, a component at high-risk of (b)(4) contamination. Identity testing for (b)(4) and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for (b)(4) levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\n2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\nYour laboratory records did not include complete data to support the analysis performed. For example, the electronic data generated by the gas chromatography system was not appropriately backed up to a separate storage location and appeared to have been deleted from the system. In addition, the paper records provided were illegible and lacked traceability to specific batches.\nReliability of data is compromised when there is a failure to maintain complete records of the conditions and data associated with all tests. Furthermore, the lack of complete data compromises the quality unit’s (QU) ability to exercise its function of ensuring compliance to applicable standards.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm failed to establish an adequate QU with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\nAppropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\nAppropriate assay test methods, procedures, or validation for testing of in-process and finished drug products (21 CFR 211.160(b)).\nEstablishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\nPerformance of an appropriate periodic (at least annual) review of drug product production (21 CFR 211.180(e)).\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nDrug Production Ceased\nWe acknowledge your commitment to cease production of all drugs at this facility.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. Should you resume manufacturing drugs, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Taizhou Jingshang Cosmetics Technology Co., Ltd., Shanhoupan Village, Hengjie Town, Luqiao District Taizhou, Zhejiang Province, China, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014244255 and ATTN: Christopher M. Jenner.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 Components with higher risk of (b)(4) contamination compared to other drug components.","Taizhou Jingshang Cosmetics Technology Co., Ltd.","taizhou-jingshang-cosmetics-technology-co-ltd-701945-04022025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftaizhou-jingshang-cosmetics-technology-co-ltd-701945-04022025","2026-10-26T08:10:09.531779+00:00","2025-05-13","701945","Mr. Zheng Liang","2026-08-19T16:48:24.345+00:00","VIA Electronic Mail","320-25-60","2025-04-02",{"id":140,"raw":141,"subject":102,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":129,"fei_number":19,"letter_url":149,"updated_at":150,"action_type":22,"case_status":23,"posted_date":151,"marcs_cms_no":152,"product_type":114,"closeout_date":19,"issuing_office":101,"recipient_name":153,"body_fetched_at":154,"delivery_method":136,"recipient_title":19,"reference_number":19,"action_taken_date":155,"medical_device_id":19,"response_letter_date":19},826,[142,143,144,101,102,13,13,13],"\u003Ctime datetime=\"2025-06-17T04:00:00Z\">06\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-06-09T04:00:00Z\">06\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freset-technology-corporation-704828-06092025\">Reset Technology Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mark Teufel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Acting CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Reset Technology Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4200 West Royal Lane, Suite # 125\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irving\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75063\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 704828\u003C\u002Fp>\u003Cp>June 9, 2025\u003C\u002Fp>\u003Cp>Dear Mark Teufel:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Englewood Cliffs, NJ, from October 29, 2024, through December 20, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ResetSmile Partial Denture Device and the at-home ResetSmile Impression Kit Device. The ResetSmile Partial Denture Device is a removeable dental appliance used to replace missing teeth and the ResetSmile Impression Kit Device is an impression kit used to help make the removeable dental appliance. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Mr. Justin S. Marks, VP Clinical Operations\u002FQuality Representative, in an email dated January 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fp>\u003Cp>Specifically, you failed to define and document procedures for process validation. For example, you have no objective evidence that the following manufacturing and cleaning processes for your ResetSmile Partial Denture Devices, for which specifications such as anatomical features, mechanical strength, or residue removal cannot be verified without \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, consistently produce a result or product that meets predetermined specifications with a high degree of assurance:\u003C\u002Fp>\u003Cp>a. \u003Cu>Scanning and CAD Design\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Scanner to generate an initial 3D scan of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\u003C\u002Fp>\u003Cp>ii. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to develop the patient-matched CAD design from the above 3D scan of the model cast but have no documented validation to support your intended use of this software application.\u003C\u002Fp>\u003Cp>b. \u003Cu>3-Dimensional (3D) Printing\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software to 3D print your ResetSmile Partial Denture Device based on the above CAD design but have no documented validations which establish the process parameter settings (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications alongside your intended use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software application.\u003C\u002Fp>\u003Cp>ii. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer; \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers; or \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers to 3D print the mold to trial fit your ResetSmile Partial Denture Device but have no documented validations which establish the process parameters (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications.\u003C\u002Fp>\u003Cp>c. \u003Cu>Post-printing Quality Control (QC) Validation (i.e., Test Method)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software, as a part of finished device acceptance, to identify conforming and nonconforming areas for your finished device through comparison of the overlay of the 3D scan of your ResetSmile Partial Denture Device (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) with the initial 3D scan (via \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Scanner software) of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\u003C\u002Fp>\u003Cp>d. \u003Cu>Cleaning\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to remove manufacturing material (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) applied to your ResetSmile Partial Denture Device prior to the Post-printing QC Validation above but have no documented validation that establishes the process parameter settings (e.g., clean time, water quality, degassing time, bath cycle, etc.) under which your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is able to consistently meet predefined specifications for cleanliness.\u003C\u002Fp>\u003Cp>ii. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> clean your ResetSmile Partial Denture Device after \u003Cstrong>(b)(4)\u003C\u002Fstrong> but have no documented validation that this \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner is able to consistently meet predefined specifications for cleanliness.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. You state process validations are not required as they have already been performed as part of the regulatory process for the FDA cleared materials used in your devices. You also state that you use FDA listed 3D scanners and computer assisted design and manufacturing (CAD\u002FCAM) software to manufacture each patient specific device (which has been validated by the manufacturer as part of their regulatory process) and that internal validation and verification of the patient specific device is performed as part of the QC Validation Process to ensure that the partial denture fits the patient model since each product has different patient specifications. As such, no corrective actions were identified. However, it is unclear how you are able to ensure (1) that predetermined specifications are consistently met with a high degree of assurance during the scanning, 3D printing, and post-printing quality control process steps described above for your ResetSmile Partial Denture Devices without validation of the software workflow for its intended use according to an established protocol with predefined acceptance criteria and (2) quality for all devices built in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle, \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines, where the results of a process (output specifications) cannot be fully verified by subsequent inspection and test. In addition, you did not provide a response on how you plan to address the lack of cleaning validations for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning processes to ensure that manufacturing material is able to be consistently removed, with a high degree of assurance, from your devices which present challenges for residue removal due to the complex geometry prevalent with such devices (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> with limited or no access, etc.). Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, the \"Control of Nonconformity Process\" procedure (8300-01; Rev.0; Effective: 10\u002F25\u002F24) and \"Non-Confirming Material Report\" form (8300-01-01; Rev.0; Effective: 10\u002F25\u002F24), which were implemented after the preannouncement of the FDA inspection on 10\u002F24\u002F24, are inadequate in that there are no requirements to document:\u003C\u002Fp>\u003Cp> Nonconformances in sufficient detail to describe what failed to meet specification(s);\u003Cbr> Evaluations of nonconformances to determine the need for investigations; and\u003Cbr> Dispositions of nonconformances.\u003C\u002Fp>\u003Cp>For example, there were no descriptions, evaluations for the need for investigations, and dispositions documented for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases of nonconforming product identified on the \"Internal Remakes log\" from 2\u002F2\u002F22 to 10\u002F28\u002F24 under three general categories: \"Failed print\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cases); \"Fabrication error\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cases); and \"Failed QC\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cases).\u003C\u002Fp>\u003Cp>We reviewed your firm's response and concluded that it is not adequate. You plan to create a new procedure to include the definition of a nonconformance, visual identification of nonconforming product, and disposition instructions; develop a new disposition log; perform a statistical analysis of the rework cases to determine if additional corrective actions are needed; and schedule training on updated procedures under corrective action report # CA011 around January 31, 2025. However, you have not identified any corrective actions to ensure that (1) your procedures and forms require that nonconformances are recorded in sufficient detail to include what failed to meet specification(s) to allow determination of potential causes and evaluations of nonconformances to determine the need for investigations and (2) retrospective review of nonconformances, for a reasonable period of time, to document what failed to meet specifications, conduct evaluations to determine the need for investigations, and record dispositions. In addition, please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for rework, including retesting and reevaluation of the nonconforming product after rework to ensure that the product meets its current approved specifications and documentation of rework and reevaluation activities, including determination of any adverse effect from the rework upon the product, in the device history record (DHR), as required by 21 CFR 820.90(b)(2).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, you failed to define and document procedures for rework which include requirements to retest and reevaluate reworked devices and document the rework and reevaluation, including adverse impact assessments on reworked devices, in the DHR. Per your VP of Clinical Operations and head Dental Technician, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of manufactured ResetSmile Partial Denture Devices undergo final adjustment (rework) during the Final Quality Control (QC) step of the \"Quality Control Validation Process\" (7506-01; Rev. 0; Effective: 2\u002F19\u002F24) which states that upon completion of the scan of the finished device, where \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas indicate the need for readjustment, \"\u003Cem>***the finished device is brought to the quality control technician for final QC analysis, including possible adjustments, and cleaning***\u003C\u002Fem>.\" All eleven (11) scans of the ResetSmile Partial Denture Devices reviewed (lot #: 20022199; 20023601; 20023705; 20024773; 20025934; 20026261; 20026272; 20026352; 20021720; 20018940; 20021572) revealed that these initial scans evaluated during the final QC step contained \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas which required adjustment. However, none of the readjustments for these devices were treated as reworks which would require additional rescans and retention of the scans to confirm specifications are met before release and documented assessment of any adverse effects.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and concluded that it is not adequate. You state the QC Validation Process (7506-01) is designed to identify and adjust potentially ill-fitting partial dentures prior to delivery to the dentist and consumer which surpasses requirements of the regulation and is in contrast to relying on the prescribing dentist to perform their own post-delivery adjustments, which is a universally accepted method. As such, no corrective actions were identified. However, your firm is not meeting the requirements of 21 CFR 820.90(b)(2) with regards to the handling of adjustments (reworks). Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>4. Failure to adequately investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, you failed to investigate or adequately investigate complaints alleged to not meet specifications, as noted in the following examples:\u003C\u002Fp>\u003Cp>i. \u003Cu>Complaint # 22952 (lot # 20021720) dated 6\u002F26\u002F24\u003C\u002Fu>: \"\u003Cem>***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***\u003C\u002Fem>.\"\u003C\u002Fp>\u003Cp>You responded to customer by sending an adjustment kit to the patient. However, there was no documented investigation into what may have caused or contributed to the device thickness.\u003C\u002Fp>\u003Cp>ii. \u003Cu>Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F24\u003C\u002Fu>: \"\u003Cem>***The partials don't t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don't fit properly***\u003C\u002Fem>.\"\u003C\u002Fp>\u003Cp>You requested photos and information on experienced issues from the customer and sent another impression kit to the patient for a remake. However, there was no documented investigation into what may have caused or contributed to the device fit issues.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. Your firm plans to assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR under corrective action report # CA013 around January 31, 2025. However, there were no corrective actions identified to retrospectively review and evaluate complaints, for a reasonable period of time, to determine (1) the need for an investigation (including justification when an investigation was not needed) and (2) definitively investigate any complaints which allege failures of your device, labeling, or packaging to meet any of its specifications. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>5. Failure to adequately maintain complaint files and adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your \"Complaint Handling Process\" procedure (8202-01; Rev.0; Effective: 6\u002F22\u002F22) is inadequate in that it fails to:\u003C\u002Fp>\u003Cp>a. Outline the criteria for when your follow-up questionnaire should be sent to complainants. For example, you emailed customers questionnaires (uncontrolled), which listed questions such as “\u003Cem>***Can you feel any roughness or sharp edges on the device that are contributing to sore spots in your mouth?***\u003C\u002Fem>” or “\u003Cem>***Does the device feel like it is placing too much pressure on the gums? In any specific area or overall tightness?***\u003C\u002Fem>” to attempt to obtain details on customer experienced issues for Complaints # 21161 (lot # 20026782) and # 56207 (lot # 20027010) but not for the following complaints:\u003C\u002Fp>\u003Cp>i. \u003Cu>Complaint # 22952 (lot # 20021720) dated 06\u002F26\u002F2024\u003C\u002Fu>: “\u003Cem>***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>ii. \u003Cem>Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F2024\u003C\u002Fem>: “\u003Cem>***The partials don’t t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don’t fit properly***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>b. Ensure that complaints include evaluations of whether they represent events which require reporting to the FDA under 21 CFR 803 (Medical Device Reporting) based on sufficient information obtained from customers to determine whether the complaints meet the definition of MDR reportable events. For example, your VP of Clinical Operations acknowledged that none of your complaint records included documented evaluations on whether the complaints were reportable, including Complaints # 22952 and # 55465 above as well as the following:\u003C\u002Fp>\u003Cp>i. \u003Cu>Complaint # 21161 (lot # 20026782) dated 10\u002F14\u002F24\u003C\u002Fu>: “\u003Cem>***The bottom is so tight, I have damaged the inside of my mouth after just one attempt. I tried again but my mouth was to [sic] sore.” The patient also stated that the device was “painful to clip in, cut me in the front of my lower teethbottom [sic]”. Your firm responded by sending an impression kit to the patient for a remake***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>ii. \u003Cu>Complaint # 56207 (lot # 20027010) dated 10\u002F23\u002F24\u003C\u002Fu>: “\u003Cem>***the bottom teeth are coming on contact with the partial causing it to move. This friction is very painful and has caused blistering… The pain that I feel goes from pressure to scratching to stabbing***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. You plan to add the definition of a complaint to your MDR and complaint procedures; include a section for MDR evaluations to the complaint form; assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR; and provide training on the revised processes under corrective action report # CA013 around January 31, 2025. In addition, you reported that none of the 1,840 complaints as of 11\u002F21\u002F24 were MDR reportable. However, there were no corrective actions identified to ensure uniformity of the complaint process by establishing criteria for when complainants are sent questionnaires and ensure that sufficient information is requested from customers to determine whether complaint events meet the definition of MDR reportability under 21 CFR 820.3(o). Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your \"Corrective &amp; Preventive Action (CAPA) Process\" (8502-01; Rev. 0; 6\u002F22\u002F22) and \"Quality Objectives Management\" (5401-01; Rev. 0; 10\u002F7\u002F24) procedures are inadequate in that:\u003C\u002Fp>\u003Cp>a. 8502-01 (nor any other procedure) does not require internal remakes of your ResetSmile Partial Denture Devices, arising from issues during manufacturing, as inputs into the CAPA process to identify existing and potential causes of nonconforming product or other quality problems, as required by 21 CFR 820.100(a)(1). For example, you remade 64 devices during the month of October 2024 due to issues categorized as failed 3D printing, fabrication errors, and failed quality control but none of this data was analyzed to identify existing and potential causes of nonconforming product or other quality problems.\u003C\u002Fp>\u003Cp>b. Neither 8502-01 nor 5401-01 require appropriate statistical methodology to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example, you only evaluate complaint data by determining whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> percentage of rework (defined as the sum of adjustments kits, remakes, and refunds sent to customers divided by the number of customer orders received for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>) exceeds \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. However, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> percentage of rework calculation includes non-quality data such as refunds and lots which are different that the lots ordered for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, you do not employ appropriate statistical methodology to any of your complaints, loosely categorized as \"issue with fit in mouth;\" \"design preference;\" \"incorrect bite\u002Focclusion;\" \"fabrication error;\" \"product not aesthetically pleasing;\" \"issue with fit on model;\" \"unknown;\" and \"wrong tooth shade,\" to detect recurring quality problems.\u003C\u002Fp>\u003Cp>c. 8502-01 does not require verification or validation of the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example, you did not verify or validate that the corrective action identified under CAPA # 002 (corrected date of 11\u002F6\u002F23) to use adjustment kits, to address the observed increase in adjustments and remake rates from fit issues, were effective and did not adversely affect your ResetSmile Partial Denture Devices prior to sending them to customers.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. You clarify that the quality data analysis is performed as part of the \"Quality Objectives Management\" (5401-01 Rev. 0) and \"Management Review\" (5600-M1 Rev. 0) processes and that there were no trends noted between May to October 2024 for the three (3) weeks where the value for percentage for rework was above \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As such, no corrective actions were identified. Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>7. Failure to establish and maintain procedures to adequately control environmental conditions, which could reasonably be expected to have an adverse effect on product quality and periodically inspect the environmental control system to verify that the system, including necessary equipment, is adequate and functioning properly, as required by 21 CFR 820.70(c).\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>a. You failed to define and document procedures to control environmental conditions for your production area consisting of \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers, used to manufacture your ResetSmile Partial Denture Devices. For example:\u003C\u002Fp>\u003Cp>i. On 11\u002F6\u002F24, the investigator observed out of specification temperatures of 92.3℉ (33.50℃) and 92.4℉ (33.56℃) on two separate temperature and humidity monitors, which were above the \"Environment Requirements\" of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℃ specified in the \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer User Guide.\" In addition, the humidity value for one of the monitors was below the requirement of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in this same guide. These out of specification values affected \u003Cstrong>(b)(4)\u003C\u002Fstrong> production lots that were being printed across \u003Cstrong>(b)(4)\u003C\u002Fstrong> different \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers at the time.\u003C\u002Fp>\u003Cp>ii. On 11\u002F19\u002F24, the investigator also observed an out of specification temperature of 95.1℉ (35.06℃) and 14.4% humidity on one temperature and humidity monitor, which were outside the temperature (\u003Cstrong>(b)(4)\u003C\u002Fstrong>℃) and humidity (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) ranges specified in the \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer User Guide.\" This out of specification temperature and humidity affected \u003Cstrong>(b)(4)\u003C\u002Fstrong> production lots that were being printed across \u003Cstrong>(b)(4)\u003C\u002Fstrong> different \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers at the time.\u003C\u002Fp>\u003Cp>Moreover, you do not regularly log the temperature and humidity values or regulate the temperature in the production area.\u003C\u002Fp>\u003Cp>b. You failed to periodically inspect your temperature and humidity monitors to ensure that they are suitable for their intended use and calibrated or evaluated for accuracy.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to calibrate your temperature and humidity sensor; set up alerts when values exceed specified requirements; control ambient humidity and temperature of the room; and develop an \"Environmental Requirements\" procedure under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\u003C\u002Fp>\u003Cp>8. Failure to ensure that all equipment used in the manufacturing process meets specified requirements and is appropriately designed, constructed, placed, and installed to facilitate maintenance, adjustment, cleaning, and use, as required by 21 CFR 820.70(g).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, you failed to meet specified placement requirements for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers, which are used to manufacture your ResetSmile Partial Denture Devices. For example, on 11\u002F19\u002F24, the investigator observed that the distance between the sides of 3D printers \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> was approximately 8 cm and the distances between the corresponding \u003Cstrong>(b)(4)\u003C\u002Fstrong> and backs of 3D printers \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were approximately 5.5 cm and 6 cm, respectively, which are all below the specified placement requirements noted in the \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer User Guide\" which requires that \"\u003Cem>***the distances of the left, right and back [sic] side space should be at least 20cm***\u003C\u002Fem>.\"\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to rearrange the printers and printer racks to accommodate the recommended spacing guidelines in the manufacturer's instructions for use; reposition the \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and document these parameters in \"Environmental Requirements\" under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\u003C\u002Fp>\u003Cp>9. Failure to establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, including documentation of training, as required by 21 CFR 820.25(b).\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your \"New Hire\u002FTraining of Personnel Process\" (SOP 6202-01; Rev. 0; Effective: 6\u002F17\u002F24) which requires both acknowledgment of training on the \"Training Acknowledgment Form\" (6202-01-04; Rev. 0; Effective: none) and identification of training needs by the senior manager on the \"Training Needs Assessment\" form (6202-01-03). For example, there were no training forms completed for the following procedures:\u003C\u002Fp>\u003Cp> \"Control of Nonconformity Process\" (SOP 8300-01; Rev. 0; Effective: 10\u002F25\u002F24)\u003Cbr> \"Complaint Handling Process\" (SOP 8202-01; Rev. 0; Effective: 06\u002F22\u002F22)\u003Cbr> \"Internal Rework Process\" (SOP 8304-01; Rev. 0, Effective: 6\u002F22\u002F24)\u003Cbr> \"External Rework Process\" (SOP 8304-02; Rev. 0, Effective: 6\u002F22\u002F24)\u003C\u002Fp>\u003Cp>In addition, there was no documented training on the 6201-01-04 form from before 10\u002F28\u002F24, which is between the dates of preannouncement (10\u002F24\u002F24) and the start of the inspection (10\u002F29\u002F24) for procedures such as (but not limited to) \"QC Validation\" (7506-01), \"Device Fabrication\" (7501-01), and \"Calibration Process\" (7600-01). This applies to \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees, including your VP of Clinical Operations; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Customer Service Representatives; \u003Cstrong>(b)(4)\u003C\u002Fstrong> CAD Technician; \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printing Technicians; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Technicians; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Lab Technicians; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Shipping\u002FReceiving personnel.&nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to conduct a review in which 6202-01-03 will be completed for all employees and additional training will be scheduled for all affected personnel for procedures noted, including completion of the 6202-01-04 form under corrective action report # CA014 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA014, and any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your ResetSmile Partial Denture Devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit any report required within 10 working days of initiating a correction or removal, initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR 806.10.\u003C\u002Fp>\u003Cp>Your firm initiated a medical device correction by providing “adjustment kits” as a corrective measure, allowing customers to modify their ResetSmile Partial Denture Devices at home. This correction was initiated to remedy dentures that do not perform as intended, i.e., cause irritation or do not fit the patient. The adjustment kit is comprised of four items: a pink emery board, a blue emery board, a sanding stick, and a transfer stick to highlight problem areas. Your firm is instructing customers to use this kit to adjust the dentures that cause gum irritation or do not fit well. CDRH determined that the gum irritation being caused by the ResetSmile Partial Denture Devices may cause temporary or medically reversible adverse health consequences. Also, in some cases, there is a reasonable probability that ill-fitting dentures will cause serious adverse health consequences. Your firm’s actions thus meet the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health. Therefore, this action is a medical device correction for which your firm is required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your ResetSmile Partial Denture and the at-home ResetSmile Impression Kit Devices, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>For your ResetSmile Partial Denture Devices, the inspection determined that you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing to produce ResetSmile Partial Denture Devices, comprised of a resin denture base material and preformed plastic denture teeth. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process includes the following specific steps: customers take at-home impressions using your firm’s impression kit; a dentist virtually reviews the scans of these at-home impressions; your firm uses the resin denture base material to make the denture bases with a 3D printer; your firm chemically bonds the preformed plastic teeth to the denture bases to fabricate the dentures; and your firm ships approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> percent of these dentures directly to customers.\u003C\u002Fp>\u003Cp>We note that (1) partial denture devices and resin denture base material are class II devices classified under 21 CFR 872.3760 and require 510(k) clearance and (2) preformed plastic teeth are class II devices classified under 21 CFR 872.3590 and generally do not require 510(k) clearance. In your response, you do not identify a 510(k) clearance for your partial denture devices. Rather, your response seems to suggest that clearance for your partial denture devices is not required because your firm uses only cleared and 510(k) exempt materials in its manufacturing process and that the resin denture base material has a clearance. However, your firm did not provide a 510(k) number for the resin denture base material intended for use in a 3D printer—rather, your firm only provided a 510(k) number for preformed plastic teeth (K060507). Therefore, premarket notification or premarket approval is required for your ResetSmile Partial Denture Devices.\u003C\u002Fp>\u003Cp>Your response did not address your at-home ResetSmile Impression Kit Devices, which the inspection revealed are shipped from your headquarters facility, located in Irving TX, directly to customers for them to use without the supervision of a dentist or other practitioner to take their own impressions for the partial dentures. Specifically, your firm’s impression kits include impression material, a retractor, a tray, and instructions which explain to customers how to take their own impressions.\u003C\u002Fp>\u003Cp>Impression material is a class II device classified under 21 CFR 872.3660 and required to have 510(k) clearance, whereas retractors and trays are class I devices and generally 510(k) exempt. Your firm claims that it has a clearance for its impression material (K221668). The 510(k) summary for K221668 states that it is “intended for use with all crowns, bridges, and orthodontic impression techniques to reproduce the structure of a patient’s teeth and gums,” and is for prescription use only. Your impression material is intended to be used by customers to take their own impression without the supervision of a dentist, and thus does not fall within this cleared indication for use. This change to the device could significantly affect the safety and effectiveness of the impression material because customers who use at-home impression kits to take their own impressions may be more likely to take improper impressions—and improper impressions can lead to improper fabrication of the denture, which can cause bone loss\u002Fresorption, irritation, sores, and TMJ dysfunction. Moreover, it is unclear whether your firm is sending the impression material to customers with a prescription from a dentist—and the labeling of the impression kit does not appear to state that it is for prescription use only. Changing a device for prescription use only to a device for over the counter use also could significantly affect the safety or effectiveness of the device.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Therefore, premarket notification or premarket approval is required for your at-home ResetSmile Impression Kit Devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identification Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the ResetSmile devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for your ResetSmile Partial Denture and ResetSmile Impression Kit Devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> technology on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>In addition, your ResetSmile Partial Denture and ResetSmile Impression Kit Devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Reset Technology Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Registration and Listing Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year.\u003C\u002Fp>\u003Cp>Your response states that you are exempt from registration and listing under 21 CFR 807.65(i) because you are a dental laboratory. Your response explains that your firm “manufactures patient specific restorative devices (removable partial dentures) based upon a prescription from a licensed dentist” and “use[s] FDA cleared materials . . . to manufacture each patient specific device and do[es] not commercially distribute these devices.” Your response further explains that you previously registered as a medical device manufacturer for preformed plastic denture teeth based on incorrect information from a regulatory consultant and have since deactivated your registration with the FDA for fiscal year 2025.\u003C\u002Fp>\u003Cp>21 CFR 807.65(i), among other things, exempts from registration and listing “[p]ersons who dispense devices to the ultimate consumer or whose major responsibility is to render a service necessary to provide the consumer (i.e., patient, physician, layman, etc.) with a device or the benefits to be derived from the use of the device; for example, a…dental laboratory…whose primary responsibility to the ultimate consumer is to dispense or provide a service through the use of a previously manufactured device.” Here, your firm is not providing a service through the use of previously manufactured devices. Rather, as discussed above, your firm manufactures and distributes partial denture devices using devices that lack required approval\u002Fclearance and manufactures and distributes impression kits comprised of devices that lack required approval\u002Fclearance.\u003C\u002Fp>\u003Cp>As of this date, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2025 for your facility located in Englewood Cliffs, NJ. 21 CFR 807.22(b). Therefore, your firm’s devices at your facility located in Englewood Cliffs, NJ, are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>We also request your attendance at a virtual Regulatory Meeting to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. This meeting will also give you an opportunity to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, by email at gina.brackett@fda.hhs.gov within 5 business days to set up a date and time for the meeting.\u003C\u002Fp>\u003Cp>Your firm’s response to the Warning Letter should be addressed to Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, and sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 704828” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Justin S. Marks, VP Clinical Operations, justin@resetsmile.com\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>See\u003C\u002Fem> Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (Oct. 2017) (“FDA has found that the directions for use necessary for health care professionals to use a device safely and effectively can be significantly different from the directions for use necessary for lay users to use that same device safely and effectively. Therefore, changing a device labeled for prescription use only to a device that is labeled for OTC use typically could significantly affect the safety or effectiveness and would likely require submission of a new 510(k).”).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMark Teufel\n\nRecipient Title\n\nActing CEO\n\nReset Technology Corporation\n\n4200 West Royal Lane, Suite # 125\n\nIrving, TX 75063\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 704828\nJune 9, 2025\nDear Mark Teufel:\nDuring an inspection of your firm located in Englewood Cliffs, NJ, from October 29, 2024, through December 20, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ResetSmile Partial Denture Device and the at-home ResetSmile Impression Kit Device. The ResetSmile Partial Denture Device is a removeable dental appliance used to replace missing teeth and the ResetSmile Impression Kit Device is an impression kit used to help make the removeable dental appliance. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Mr. Justin S. Marks, VP Clinical Operations\u002FQuality Representative, in an email dated January 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically, you failed to define and document procedures for process validation. For example, you have no objective evidence that the following manufacturing and cleaning processes for your ResetSmile Partial Denture Devices, for which specifications such as anatomical features, mechanical strength, or residue removal cannot be verified without (b)(4) testing, consistently produce a result or product that meets predetermined specifications with a high degree of assurance:\na. Scanning and CAD Design\ni. You utilize the (b)(4) Dental Scanner to generate an initial 3D scan of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\nii. You utilize the (b)(4) to develop the patient-matched CAD design from the above 3D scan of the model cast but have no documented validation to support your intended use of this software application.\nb. 3-Dimensional (3D) Printing\ni. You utilize (b)(4) 3D Printers with the (b)(4) software to 3D print your ResetSmile Partial Denture Device based on the above CAD design but have no documented validations which establish the process parameter settings (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications alongside your intended use of the (b)(4) software application.\nii. You utilize the (b)(4) 3D Printer; (b)(4) 3D Printers; or (b)(4) 3D Printers to 3D print the mold to trial fit your ResetSmile Partial Denture Device but have no documented validations which establish the process parameters (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications.\nc. Post-printing Quality Control (QC) Validation (i.e., Test Method)\ni. You utilize the (b)(4) software, as a part of finished device acceptance, to identify conforming and nonconforming areas for your finished device through comparison of the overlay of the 3D scan of your ResetSmile Partial Denture Device ((b)(4)) with the initial 3D scan (via (b)(4) Dental Scanner software) of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\nd. Cleaning\ni. You utilize the (b)(4) to remove manufacturing material (e.g., (b)(4)) applied to your ResetSmile Partial Denture Device prior to the Post-printing QC Validation above but have no documented validation that establishes the process parameter settings (e.g., clean time, water quality, degassing time, bath cycle, etc.) under which your (b)(4) is able to consistently meet predefined specifications for cleanliness.\nii. You utilize the (b)(4) to (b)(4) clean your ResetSmile Partial Denture Device after (b)(4) but have no documented validation that this (b)(4) cleaner is able to consistently meet predefined specifications for cleanliness.\nWe reviewed your firm's response and conclude that it is not adequate. You state process validations are not required as they have already been performed as part of the regulatory process for the FDA cleared materials used in your devices. You also state that you use FDA listed 3D scanners and computer assisted design and manufacturing (CAD\u002FCAM) software to manufacture each patient specific device (which has been validated by the manufacturer as part of their regulatory process) and that internal validation and verification of the patient specific device is performed as part of the QC Validation Process to ensure that the partial denture fits the patient model since each product has different patient specifications. As such, no corrective actions were identified. However, it is unclear how you are able to ensure (1) that predetermined specifications are consistently met with a high degree of assurance during the scanning, 3D printing, and post-printing quality control process steps described above for your ResetSmile Partial Denture Devices without validation of the software workflow for its intended use according to an established protocol with predefined acceptance criteria and (2) quality for all devices built in a (b)(4) cycle, (b)(4) cycles, and (b)(4) machines, where the results of a process (output specifications) cannot be fully verified by subsequent inspection and test. In addition, you did not provide a response on how you plan to address the lack of cleaning validations for your (b)(4) and (b)(4) cleaning processes to ensure that manufacturing material is able to be consistently removed, with a high degree of assurance, from your devices which present challenges for residue removal due to the complex geometry prevalent with such devices (e.g., (b)(4) with limited or no access, etc.). Therefore, please provide a response on how you plan to address the above deficiencies.\n2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\nSpecifically, the \"Control of Nonconformity Process\" procedure (8300-01; Rev.0; Effective: 10\u002F25\u002F24) and \"Non-Confirming Material Report\" form (8300-01-01; Rev.0; Effective: 10\u002F25\u002F24), which were implemented after the preannouncement of the FDA inspection on 10\u002F24\u002F24, are inadequate in that there are no requirements to document:\n Nonconformances in sufficient detail to describe what failed to meet specification(s);\n Evaluations of nonconformances to determine the need for investigations; and\n Dispositions of nonconformances.\nFor example, there were no descriptions, evaluations for the need for investigations, and dispositions documented for (b)(4) cases of nonconforming product identified on the \"Internal Remakes log\" from 2\u002F2\u002F22 to 10\u002F28\u002F24 under three general categories: \"Failed print\" ((b)(4) cases); \"Fabrication error\" ((b)(4) cases); and \"Failed QC\" ((b)(4) cases).\nWe reviewed your firm's response and concluded that it is not adequate. You plan to create a new procedure to include the definition of a nonconformance, visual identification of nonconforming product, and disposition instructions; develop a new disposition log; perform a statistical analysis of the rework cases to determine if additional corrective actions are needed; and schedule training on updated procedures under corrective action report # CA011 around January 31, 2025. However, you have not identified any corrective actions to ensure that (1) your procedures and forms require that nonconformances are recorded in sufficient detail to include what failed to meet specification(s) to allow determination of potential causes and evaluations of nonconformances to determine the need for investigations and (2) retrospective review of nonconformances, for a reasonable period of time, to document what failed to meet specifications, conduct evaluations to determine the need for investigations, and record dispositions. In addition, please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n3. Failure to establish and maintain procedures for rework, including retesting and reevaluation of the nonconforming product after rework to ensure that the product meets its current approved specifications and documentation of rework and reevaluation activities, including determination of any adverse effect from the rework upon the product, in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\nSpecifically, you failed to define and document procedures for rework which include requirements to retest and reevaluate reworked devices and document the rework and reevaluation, including adverse impact assessments on reworked devices, in the DHR. Per your VP of Clinical Operations and head Dental Technician, approximately (b)(4) of manufactured ResetSmile Partial Denture Devices undergo final adjustment (rework) during the Final Quality Control (QC) step of the \"Quality Control Validation Process\" (7506-01; Rev. 0; Effective: 2\u002F19\u002F24) which states that upon completion of the scan of the finished device, where (b)(4) areas indicate the need for readjustment, \"***the finished device is brought to the quality control technician for final QC analysis, including possible adjustments, and cleaning***.\" All eleven (11) scans of the ResetSmile Partial Denture Devices reviewed (lot #: 20022199; 20023601; 20023705; 20024773; 20025934; 20026261; 20026272; 20026352; 20021720; 20018940; 20021572) revealed that these initial scans evaluated during the final QC step contained (b)(4) areas which required adjustment. However, none of the readjustments for these devices were treated as reworks which would require additional rescans and retention of the scans to confirm specifications are met before release and documented assessment of any adverse effects.\nWe reviewed your firm's response and concluded that it is not adequate. You state the QC Validation Process (7506-01) is designed to identify and adjust potentially ill-fitting partial dentures prior to delivery to the dentist and consumer which surpasses requirements of the regulation and is in contrast to relying on the prescribing dentist to perform their own post-delivery adjustments, which is a universally accepted method. As such, no corrective actions were identified. However, your firm is not meeting the requirements of 21 CFR 820.90(b)(2) with regards to the handling of adjustments (reworks). Therefore, please provide a response on how you plan to address the above deficiencies.\n4. Failure to adequately investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).\nSpecifically, you failed to investigate or adequately investigate complaints alleged to not meet specifications, as noted in the following examples:\ni. Complaint # 22952 (lot # 20021720) dated 6\u002F26\u002F24: \"***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***.\"\nYou responded to customer by sending an adjustment kit to the patient. However, there was no documented investigation into what may have caused or contributed to the device thickness.\nii. Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F24: \"***The partials don't t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don't fit properly***.\"\nYou requested photos and information on experienced issues from the customer and sent another impression kit to the patient for a remake. However, there was no documented investigation into what may have caused or contributed to the device fit issues.\nWe reviewed your firm's response and conclude that it is not adequate. Your firm plans to assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR under corrective action report # CA013 around January 31, 2025. However, there were no corrective actions identified to retrospectively review and evaluate complaints, for a reasonable period of time, to determine (1) the need for an investigation (including justification when an investigation was not needed) and (2) definitively investigate any complaints which allege failures of your device, labeling, or packaging to meet any of its specifications. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n5. Failure to adequately maintain complaint files and adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).\nSpecifically, your \"Complaint Handling Process\" procedure (8202-01; Rev.0; Effective: 6\u002F22\u002F22) is inadequate in that it fails to:\na. Outline the criteria for when your follow-up questionnaire should be sent to complainants. For example, you emailed customers questionnaires (uncontrolled), which listed questions such as “***Can you feel any roughness or sharp edges on the device that are contributing to sore spots in your mouth?***” or “***Does the device feel like it is placing too much pressure on the gums? In any specific area or overall tightness?***” to attempt to obtain details on customer experienced issues for Complaints # 21161 (lot # 20026782) and # 56207 (lot # 20027010) but not for the following complaints:\ni. Complaint # 22952 (lot # 20021720) dated 06\u002F26\u002F2024: “***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***.”\nii. Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F2024: “***The partials don’t t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don’t fit properly***.”\nb. Ensure that complaints include evaluations of whether they represent events which require reporting to the FDA under 21 CFR 803 (Medical Device Reporting) based on sufficient information obtained from customers to determine whether the complaints meet the definition of MDR reportable events. For example, your VP of Clinical Operations acknowledged that none of your complaint records included documented evaluations on whether the complaints were reportable, including Complaints # 22952 and # 55465 above as well as the following:\ni. Complaint # 21161 (lot # 20026782) dated 10\u002F14\u002F24: “***The bottom is so tight, I have damaged the inside of my mouth after just one attempt. I tried again but my mouth was to [sic] sore.” The patient also stated that the device was “painful to clip in, cut me in the front of my lower teethbottom [sic]”. Your firm responded by sending an impression kit to the patient for a remake***.”\nii. Complaint # 56207 (lot # 20027010) dated 10\u002F23\u002F24: “***the bottom teeth are coming on contact with the partial causing it to move. This friction is very painful and has caused blistering… The pain that I feel goes from pressure to scratching to stabbing***.”\nWe reviewed your firm's response and conclude that it is not adequate. You plan to add the definition of a complaint to your MDR and complaint procedures; include a section for MDR evaluations to the complaint form; assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR; and provide training on the revised processes under corrective action report # CA013 around January 31, 2025. In addition, you reported that none of the 1,840 complaints as of 11\u002F21\u002F24 were MDR reportable. However, there were no corrective actions identified to ensure uniformity of the complaint process by establishing criteria for when complainants are sent questionnaires and ensure that sufficient information is requested from customers to determine whether complaint events meet the definition of MDR reportability under 21 CFR 820.3(o). Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n6. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your \"Corrective & Preventive Action (CAPA) Process\" (8502-01; Rev. 0; 6\u002F22\u002F22) and \"Quality Objectives Management\" (5401-01; Rev. 0; 10\u002F7\u002F24) procedures are inadequate in that:\na. 8502-01 (nor any other procedure) does not require internal remakes of your ResetSmile Partial Denture Devices, arising from issues during manufacturing, as inputs into the CAPA process to identify existing and potential causes of nonconforming product or other quality problems, as required by 21 CFR 820.100(a)(1). For example, you remade 64 devices during the month of October 2024 due to issues categorized as failed 3D printing, fabrication errors, and failed quality control but none of this data was analyzed to identify existing and potential causes of nonconforming product or other quality problems.\nb. Neither 8502-01 nor 5401-01 require appropriate statistical methodology to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example, you only evaluate complaint data by determining whether the (b)(4) percentage of rework (defined as the sum of adjustments kits, remakes, and refunds sent to customers divided by the number of customer orders received for the (b)(4)) exceeds (b)(4)%. However, the (b)(4) percentage of rework calculation includes non-quality data such as refunds and lots which are different that the lots ordered for the (b)(4). Therefore, you do not employ appropriate statistical methodology to any of your complaints, loosely categorized as \"issue with fit in mouth;\" \"design preference;\" \"incorrect bite\u002Focclusion;\" \"fabrication error;\" \"product not aesthetically pleasing;\" \"issue with fit on model;\" \"unknown;\" and \"wrong tooth shade,\" to detect recurring quality problems.\nc. 8502-01 does not require verification or validation of the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example, you did not verify or validate that the corrective action identified under CAPA # 002 (corrected date of 11\u002F6\u002F23) to use adjustment kits, to address the observed increase in adjustments and remake rates from fit issues, were effective and did not adversely affect your ResetSmile Partial Denture Devices prior to sending them to customers.\nWe reviewed your firm's response and conclude that it is not adequate. You clarify that the quality data analysis is performed as part of the \"Quality Objectives Management\" (5401-01 Rev. 0) and \"Management Review\" (5600-M1 Rev. 0) processes and that there were no trends noted between May to October 2024 for the three (3) weeks where the value for percentage for rework was above (b)(4). As such, no corrective actions were identified. Therefore, please provide a response on how you plan to address the above deficiencies.\n7. Failure to establish and maintain procedures to adequately control environmental conditions, which could reasonably be expected to have an adverse effect on product quality and periodically inspect the environmental control system to verify that the system, including necessary equipment, is adequate and functioning properly, as required by 21 CFR 820.70(c).\nSpecifically:\na. You failed to define and document procedures to control environmental conditions for your production area consisting of (b)(4) 3D Printers, used to manufacture your ResetSmile Partial Denture Devices. For example:\ni. On 11\u002F6\u002F24, the investigator observed out of specification temperatures of 92.3℉ (33.50℃) and 92.4℉ (33.56℃) on two separate temperature and humidity monitors, which were above the \"Environment Requirements\" of (b)(4)℃ specified in the \"(b)(4) 3D Printer User Guide.\" In addition, the humidity value for one of the monitors was below the requirement of (b)(4) in this same guide. These out of specification values affected (b)(4) production lots that were being printed across (b)(4) different (b)(4) 3D Printers at the time.\nii. On 11\u002F19\u002F24, the investigator also observed an out of specification temperature of 95.1℉ (35.06℃) and 14.4% humidity on one temperature and humidity monitor, which were outside the temperature ((b)(4)℃) and humidity ((b)(4)) ranges specified in the \"(b)(4) 3D Printer User Guide.\" This out of specification temperature and humidity affected (b)(4) production lots that were being printed across (b)(4) different (b)(4) 3D Printers at the time.\nMoreover, you do not regularly log the temperature and humidity values or regulate the temperature in the production area.\nb. You failed to periodically inspect your temperature and humidity monitors to ensure that they are suitable for their intended use and calibrated or evaluated for accuracy.\nWe reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to calibrate your temperature and humidity sensor; set up alerts when values exceed specified requirements; control ambient humidity and temperature of the room; and develop an \"Environmental Requirements\" procedure under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\n8. Failure to ensure that all equipment used in the manufacturing process meets specified requirements and is appropriately designed, constructed, placed, and installed to facilitate maintenance, adjustment, cleaning, and use, as required by 21 CFR 820.70(g).\nSpecifically, you failed to meet specified placement requirements for your (b)(4) 3D Printers, which are used to manufacture your ResetSmile Partial Denture Devices. For example, on 11\u002F19\u002F24, the investigator observed that the distance between the sides of 3D printers (b)(4) and (b)(4) and (b)(4) and (b)(4) was approximately 8 cm and the distances between the corresponding (b)(4) and backs of 3D printers (b)(4) and (b)(4) were approximately 5.5 cm and 6 cm, respectively, which are all below the specified placement requirements noted in the \"(b)(4) 3D Printer User Guide\" which requires that \"***the distances of the left, right and back [sic] side space should be at least 20cm***.\"\nWe reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to rearrange the printers and printer racks to accommodate the recommended spacing guidelines in the manufacturer's instructions for use; reposition the (b)(4); and document these parameters in \"Environmental Requirements\" under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\n9. Failure to establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, including documentation of training, as required by 21 CFR 820.25(b).\nSpecifically, you failed to implement your \"New Hire\u002FTraining of Personnel Process\" (SOP 6202-01; Rev. 0; Effective: 6\u002F17\u002F24) which requires both acknowledgment of training on the \"Training Acknowledgment Form\" (6202-01-04; Rev. 0; Effective: none) and identification of training needs by the senior manager on the \"Training Needs Assessment\" form (6202-01-03). For example, there were no training forms completed for the following procedures:\n \"Control of Nonconformity Process\" (SOP 8300-01; Rev. 0; Effective: 10\u002F25\u002F24)\n \"Complaint Handling Process\" (SOP 8202-01; Rev. 0; Effective: 06\u002F22\u002F22)\n \"Internal Rework Process\" (SOP 8304-01; Rev. 0, Effective: 6\u002F22\u002F24)\n \"External Rework Process\" (SOP 8304-02; Rev. 0, Effective: 6\u002F22\u002F24)\nIn addition, there was no documented training on the 6201-01-04 form from before 10\u002F28\u002F24, which is between the dates of preannouncement (10\u002F24\u002F24) and the start of the inspection (10\u002F29\u002F24) for procedures such as (but not limited to) \"QC Validation\" (7506-01), \"Device Fabrication\" (7501-01), and \"Calibration Process\" (7600-01). This applies to (b)(4) employees, including your VP of Clinical Operations; (b)(4) Customer Service Representatives; (b)(4) CAD Technician; (b)(4) 3D Printing Technicians; (b)(4) Dental Technicians; (b)(4) Dental Lab Technicians; and (b)(4) Shipping\u002FReceiving personnel.\nWe reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to conduct a review in which 6202-01-03 will be completed for all employees and additional training will be scheduled for all affected personnel for procedures noted, including completion of the 6202-01-04 form under corrective action report # CA014 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA014, and any supporting evidence.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your ResetSmile Partial Denture Devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\nFailure to submit any report required within 10 working days of initiating a correction or removal, initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR 806.10.\nYour firm initiated a medical device correction by providing “adjustment kits” as a corrective measure, allowing customers to modify their ResetSmile Partial Denture Devices at home. This correction was initiated to remedy dentures that do not perform as intended, i.e., cause irritation or do not fit the patient. The adjustment kit is comprised of four items: a pink emery board, a blue emery board, a sanding stick, and a transfer stick to highlight problem areas. Your firm is instructing customers to use this kit to adjust the dentures that cause gum irritation or do not fit well. CDRH determined that the gum irritation being caused by the ResetSmile Partial Denture Devices may cause temporary or medically reversible adverse health consequences. Also, in some cases, there is a reasonable probability that ill-fitting dentures will cause serious adverse health consequences. Your firm’s actions thus meet the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health. Therefore, this action is a medical device correction for which your firm is required to submit a Report of Correction or Removal to FDA.\nUnapproved Device Violation(s)\nOur inspection also revealed that your ResetSmile Partial Denture and the at-home ResetSmile Impression Kit Devices, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nFor your ResetSmile Partial Denture Devices, the inspection determined that you use (b)(4) manufacturing to produce ResetSmile Partial Denture Devices, comprised of a resin denture base material and preformed plastic denture teeth. The (b)(4) manufacturing process includes the following specific steps: customers take at-home impressions using your firm’s impression kit; a dentist virtually reviews the scans of these at-home impressions; your firm uses the resin denture base material to make the denture bases with a 3D printer; your firm chemically bonds the preformed plastic teeth to the denture bases to fabricate the dentures; and your firm ships approximately (b)(4) percent of these dentures directly to customers.\nWe note that (1) partial denture devices and resin denture base material are class II devices classified under 21 CFR 872.3760 and require 510(k) clearance and (2) preformed plastic teeth are class II devices classified under 21 CFR 872.3590 and generally do not require 510(k) clearance. In your response, you do not identify a 510(k) clearance for your partial denture devices. Rather, your response seems to suggest that clearance for your partial denture devices is not required because your firm uses only cleared and 510(k) exempt materials in its manufacturing process and that the resin denture base material has a clearance. However, your firm did not provide a 510(k) number for the resin denture base material intended for use in a 3D printer—rather, your firm only provided a 510(k) number for preformed plastic teeth (K060507). Therefore, premarket notification or premarket approval is required for your ResetSmile Partial Denture Devices.\nYour response did not address your at-home ResetSmile Impression Kit Devices, which the inspection revealed are shipped from your headquarters facility, located in Irving TX, directly to customers for them to use without the supervision of a dentist or other practitioner to take their own impressions for the partial dentures. Specifically, your firm’s impression kits include impression material, a retractor, a tray, and instructions which explain to customers how to take their own impressions.\nImpression material is a class II device classified under 21 CFR 872.3660 and required to have 510(k) clearance, whereas retractors and trays are class I devices and generally 510(k) exempt. Your firm claims that it has a clearance for its impression material (K221668). The 510(k) summary for K221668 states that it is “intended for use with all crowns, bridges, and orthodontic impression techniques to reproduce the structure of a patient’s teeth and gums,” and is for prescription use only. Your impression material is intended to be used by customers to take their own impression without the supervision of a dentist, and thus does not fall within this cleared indication for use. This change to the device could significantly affect the safety and effectiveness of the impression material because customers who use at-home impression kits to take their own impressions may be more likely to take improper impressions—and improper impressions can lead to improper fabrication of the denture, which can cause bone loss\u002Fresorption, irritation, sores, and TMJ dysfunction. Moreover, it is unclear whether your firm is sending the impression material to customers with a prescription from a dentist—and the labeling of the impression kit does not appear to state that it is for prescription use only. Changing a device for prescription use only to a device for over the counter use also could significantly affect the safety or effectiveness of the device.1 Therefore, premarket notification or premarket approval is required for your at-home ResetSmile Impression Kit Devices.\nUnique Device Identification Violation(s)\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the ResetSmile devices do not bear such a UDI.\nSpecifically, the labels for your ResetSmile Partial Denture and ResetSmile Impression Kit Devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses (b)(4) technology on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(2)).\nIn addition, your ResetSmile Partial Denture and ResetSmile Impression Kit Devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Reset Technology Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nRegistration and Listing Violation(s)\nUnder section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year.\nYour response states that you are exempt from registration and listing under 21 CFR 807.65(i) because you are a dental laboratory. Your response explains that your firm “manufactures patient specific restorative devices (removable partial dentures) based upon a prescription from a licensed dentist” and “use[s] FDA cleared materials . . . to manufacture each patient specific device and do[es] not commercially distribute these devices.” Your response further explains that you previously registered as a medical device manufacturer for preformed plastic denture teeth based on incorrect information from a regulatory consultant and have since deactivated your registration with the FDA for fiscal year 2025.\n21 CFR 807.65(i), among other things, exempts from registration and listing “[p]ersons who dispense devices to the ultimate consumer or whose major responsibility is to render a service necessary to provide the consumer (i.e., patient, physician, layman, etc.) with a device or the benefits to be derived from the use of the device; for example, a…dental laboratory…whose primary responsibility to the ultimate consumer is to dispense or provide a service through the use of a previously manufactured device.” Here, your firm is not providing a service through the use of previously manufactured devices. Rather, as discussed above, your firm manufactures and distributes partial denture devices using devices that lack required approval\u002Fclearance and manufactures and distributes impression kits comprised of devices that lack required approval\u002Fclearance.\nAs of this date, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2025 for your facility located in Englewood Cliffs, NJ. 21 CFR 807.22(b). Therefore, your firm’s devices at your facility located in Englewood Cliffs, NJ, are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nWe also request your attendance at a virtual Regulatory Meeting to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. This meeting will also give you an opportunity to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, by email at gina.brackett@fda.hhs.gov within 5 business days to set up a date and time for the meeting.\nYour firm’s response to the Warning Letter should be addressed to Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, and sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 704828” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Justin S. Marks, VP Clinical Operations, justin@resetsmile.com\n_____________________________\n1 See Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (Oct. 2017) (“FDA has found that the directions for use necessary for health care professionals to use a device safely and effectively can be significantly different from the directions for use necessary for lay users to use that same device safely and effectively. Therefore, changing a device labeled for prescription use only to a device that is labeled for OTC use typically could significantly affect the safety or effectiveness and would likely require submission of a new 510(k).”).","Reset Technology Corporation","reset-technology-corporation-704828-06092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freset-technology-corporation-704828-06092025","2026-10-26T08:09:48.8589+00:00","2025-06-17","704828","Mark Teufel","2026-08-19T16:39:59.227+00:00","2025-06-09",{"id":157,"raw":158,"subject":163,"body_html":164,"body_text":165,"firm_name":166,"letter_id":167,"created_at":108,"fei_number":19,"letter_url":168,"updated_at":169,"action_type":22,"case_status":23,"posted_date":170,"marcs_cms_no":171,"product_type":172,"closeout_date":19,"issuing_office":162,"recipient_name":173,"body_fetched_at":174,"delivery_method":175,"recipient_title":19,"reference_number":19,"action_taken_date":176,"medical_device_id":19,"response_letter_date":19},2156,[159,160,161,162,163,13,13,13],"\u003Ctime datetime=\"2023-03-21T13:20:00Z\">03\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-16T04:00:00Z\">03\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarina-technology-llc-652997-03162023\">Marina Technology LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nicholas Gollust and Robert Sunderland\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Marina Technology LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6080 Center Drive, Floor 6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Los Angeles\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90045\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nick@marinatech.com\"> nick@marinatech.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@marinatech.co\"> info@marinatech.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 16, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Nicholas Gollust and Robert Sunderland:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.marinatech.co and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.marinatech.co revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Aquabar Berry Blast, Aquabar Peach Ice, and Aquabar Rainbow Ice.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2301909, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003Cbr>\n\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nMarina Technology, LLC\u003Cbr>\nAttn: Sam Rosenberg and Nicholas\u003Cbr>\nsam@marinavape.com\u003Cbr>\nnick@marinavape.com\u003C\u002Fp>\n\n\u003Cp>Marina Vape LLC\u003Cbr>\nAttn: Nebil Kabir\u003Cbr>\n4943 McConnell Ave Ste N\u003Cbr>\nLos Angeles, CA 90066\u003Cbr>\ninfo@marinatech.co\u003C\u002Fp>\n\n\u003Cp>Key-Systems GmbH\u003Cbr>\nabuse@key-systems.net\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\u003Cp>Element Vape\u003Cbr>\n300 W. Valley Blvd, Unit 23\u003Cbr>\nAlhambra, CA 91803\u003Cbr>\ncustomerservice@elementvape.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nNicholas Gollust and Robert Sunderland\n\nMarina Technology LLC\n\n6080 Center Drive, Floor 6\n\nLos Angeles, CA 90045\n\nUnited States\n\nnick@marinatech.com\n\ninfo@marinatech.co\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMarch 16, 2023\n\nWARNING LETTER\n\nDear Nicholas Gollust and Robert Sunderland:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.marinatech.co and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.marinatech.co revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Aquabar Berry Blast, Aquabar Peach Ice, and Aquabar Rainbow Ice.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2301909, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nMarina Technology, LLC\n\nAttn: Sam Rosenberg and Nicholas\n\nsam@marinavape.com\n\nnick@marinavape.com\n\nMarina Vape LLC\n\nAttn: Nebil Kabir\n\n4943 McConnell Ave Ste N\n\nLos Angeles, CA 90066\n\ninfo@marinatech.co\n\nKey-Systems GmbH\n\nabuse@key-systems.net\n\nShopify, Inc.\n\nabuse@shopify.com\n\nElement Vape\n\n300 W. Valley Blvd, Unit 23\n\nAlhambra, CA 91803\n\ncustomerservice@elementvape.com","Marina Technology LLC","marina-technology-llc-652997-03162023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarina-technology-llc-652997-03162023","2026-10-26T08:09:20.478436+00:00","2023-03-21","652997","Tobacco","Nicholas Gollust and Robert Sunderland","2026-08-20T01:11:27.55+00:00","VIA UPS and Electronic Mail","2023-03-16",{"id":178,"raw":179,"subject":38,"body_html":184,"body_text":185,"firm_name":186,"letter_id":187,"created_at":188,"fei_number":19,"letter_url":189,"updated_at":190,"action_type":22,"case_status":23,"posted_date":191,"marcs_cms_no":192,"product_type":26,"closeout_date":19,"issuing_office":183,"recipient_name":193,"body_fetched_at":194,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":195,"medical_device_id":19,"response_letter_date":19},3550,[180,181,182,183,38,13,13,13],"\u003Ctime datetime=\"2021-02-09T14:20:00Z\">02\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-03T05:00:00Z\">02\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshangrao-chunyu-technology-co-ltd-610194-02032021\">ShangRao Chunyu Technology Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Daniel Suer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ShangRao Chunyu Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Xuri Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shangrao Economic-Technical Development Area\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shangrao Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangxi Sheng\u003C\u002Fspan>, \u003Cspan>334100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-24\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 3, 2021\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Suer:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as Instant – Hand Sanitizer – Moisturizing. This drug product was declared to be manufactured at your facility, Shangrao Chunyu Technology Co., Ltd., FEI 3015958566, at Xuri Zone, Shangrao Economic-Technical Development Area, Shangrao, Jiangxi 334100, China. Following an attempt to import Instant – Hand Sanitizer – Moisturizing into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Instant – Hand Sanitizer – Moisturizing, declared to be manufactured at your facility, is labeled to contain 75% of the active ingredient alcohol ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of only 58% ethanol volume\u002Fvolume. This hand sanitizer drug product is adulterated under section 501(c) of the FD&amp;C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its label.\u003C\u002Fp>\n\n\u003Cp>CDC recommends\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>On September 8, 2020, FDA held a teleconference with you and Pragmatic Compliance, LLC, your registered U.S. Agent. We requested additional information concerning your CGMP operations, including test methods for your finished product. In your response, you provided your test method for release of finished hand sanitizer products. The method you submitted uses a \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;that is unsuitable for the testing of finished hand sanitizers that contain materials other than ethanol and water in their \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of this unsuitable device to test your finished hand sanitizer products violates CGMP requirements (see 21 CFR 211.160(b)(requiring the use of scientifically sound and appropriate test procedures to, among other things, assure that drug products conform to appropriate standards of identity, strength, quality, and purity).\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed investigation into how the hand sanitizer drug product described above, which was labeled as containing 75% ethanol, in fact contained 58% ethanol.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• For all batches distributed to the U.S., provide a third-party analysis using validated test methods for ethanol content. For out-of-specification (OOS) batches, provide your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the U.S.\u003Cbr>\n• A complete, comprehensive, and independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n\u003Cbr>\nThe subpotency of a drug product declared as manufactured at your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.2\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on November 6, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3015958566 and ATTN: Bryce Hammer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nJerry Doane\u003Cbr>\nPragmatic Compliance LLC\u003Cbr>\n15815 SW 11th Court Rd\u003Cbr>\nOcala, FL 34473-8916\u003C\u002Fp>\n\n\u003Cp>__________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of a hand sanitizer product declared as manufactured at your facility, a review of the drug product’s labeling further indicates that the product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Daniel Suer\n\nRecipient Title\n\nCEO\n\nShangRao Chunyu Technology Co., Ltd.\n\nXuri Zone\n\nShangrao Economic-Technical Development Area\n\nShangrao Shi\n\nJiangxi Sheng, 334100\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-24\n\nFebruary 3, 2021\n\nDear Mr. Suer:\n\nYour firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as Instant – Hand Sanitizer – Moisturizing. This drug product was declared to be manufactured at your facility, Shangrao Chunyu Technology Co., Ltd., FEI 3015958566, at Xuri Zone, Shangrao Economic-Technical Development Area, Shangrao, Jiangxi 334100, China. Following an attempt to import Instant – Hand Sanitizer – Moisturizing into the United States, it was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nAdulteration Violation\n\nInstant – Hand Sanitizer – Moisturizing, declared to be manufactured at your facility, is labeled to contain 75% of the active ingredient alcohol ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of only 58% ethanol volume\u002Fvolume. This hand sanitizer drug product is adulterated under section 501(c) of the FD&C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its label.\n\nCDC recommends1 that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOn September 8, 2020, FDA held a teleconference with you and Pragmatic Compliance, LLC, your registered U.S. Agent. We requested additional information concerning your CGMP operations, including test methods for your finished product. In your response, you provided your test method for release of finished hand sanitizer products. The method you submitted uses a (b)(4) that is unsuitable for the testing of finished hand sanitizers that contain materials other than ethanol and water in their (b)(4). The use of this unsuitable device to test your finished hand sanitizer products violates CGMP requirements (see 21 CFR 211.160(b)(requiring the use of scientifically sound and appropriate test procedures to, among other things, assure that drug products conform to appropriate standards of identity, strength, quality, and purity).\n\nIn response to this letter, provide the following:\n\n• A detailed investigation into how the hand sanitizer drug product described above, which was labeled as containing 75% ethanol, in fact contained 58% ethanol.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• For all batches distributed to the U.S., provide a third-party analysis using validated test methods for ethanol content. For out-of-specification (OOS) batches, provide your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\n\n• Copies of the complete batch records for all batches distributed to the U.S.\n\n• A complete, comprehensive, and independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nThe subpotency of a drug product declared as manufactured at your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.2\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on November 6, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3015958566 and ATTN: Bryce Hammer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered U.S. Agent\n\nJerry Doane\n\nPragmatic Compliance LLC\n\n15815 SW 11th Court Rd\n\nOcala, FL 34473-8916\n\n__________________________________\n\n1 https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of a hand sanitizer product declared as manufactured at your facility, a review of the drug product’s labeling further indicates that the product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","ShangRao Chunyu Technology Co., Ltd.","shangrao-chunyu-technology-co-ltd-610194-02032021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshangrao-chunyu-technology-co-ltd-610194-02032021","2026-10-26T08:09:55.989565+00:00","2021-02-09","610194","Mr. Daniel Suer","2026-08-20T03:24:38.691+00:00","2021-02-03",9,{"510k":198,"classification":199,"enforcement":200,"event":201,"event_backfill":202,"pma":203,"warning_letter":204},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]